Introduction To Chemical Pathology
Standard Answer:
1. DISCUSS THE ROLE OF THE CHEMICAL PATHOLOGIST IN THE PRACTICE OF CLINICAL MEDICINE The chemical pathologist plays a multifaceted and indispensable role in modern clinical medicine, serving as a bridge between the basic sciences and patient care. Their responsibilities extend far beyond the laboratory bench to encompass direct patient care, consultation, and healthcare management. Clinical Consultation and Diagnostic Support Chemical pathologists serve as expert consultants to clinicians, helping to: · Select appropriate investigations for specific clinical presentations · Interpret complex laboratory results in the context of the patient's clinical picture · Advise on the diagnostic utility and limitations of various tests · Recommend additional investigations when results are equivocal or unexpected Laboratory Management and Quality Assurance As directors of clinical chemistry laboratories, chemical pathologists are responsible for: · Ensuring analytical quality through internal quality control and external quality assessment schemes · Validating new methods and technologies before their introduction into clinical practice · Establishing reference ranges appropriate for the local population · Managing laboratory staff and ensuring adherence to best practice guidelines Clinical Governance and Patient Safety The chemical pathologist contributes to patient safety through: · Identifying and preventing errors at all stages of the testing process (pre-analytical, analytical, post-analytical) · Developing and implementing clinical guidelines for test utilization · Auditing laboratory practice and outcomes · Investigating adverse events related to laboratory testing Teaching and Training Chemical pathologists are actively involved in: · Teaching medical students and postgraduate trainees · Training junior doctors in the appropriate use of laboratory tests · Continuing professional development for laboratory staff · Communicating complex scientific concepts to clinical colleagues Research and Development The chemical pathologist contributes to the advancement of medicine through: · Clinical research to validate new biomarkers · Translational research to bring scientific discoveries to the bedside · Outcomes research to evaluate the clinical utility of testing strategies · Health services research to optimize laboratory service delivery 2. DEFINITION OF PATHOLOGY AND CHEMICAL PATHOLOGY. SYNONYMS OF CHEMICAL PATHOLOGY Pathology Pathology is the scientific study of disease processes. It encompasses the structural, functional, and biochemical changes that occur in cells, tissues, and organs as a result of disease. The term derives from the Greek words "pathos" (suffering) and "logos" (study). Pathology is broadly divided into: Category Focus Anatomical Pathology Structural changes in tissues and organs (gross and microscopic) Clinical Pathology Laboratory analysis of body fluids and tissues for diagnostic purposes Chemical Pathology Chemical Pathology (also known as Clinical Biochemistry, Clinical Chemistry, or Metabolic Medicine) is the branch of pathology concerned with the biochemical analysis of body fluids and tissues for the diagnosis, monitoring, and management of disease. It involves: · Quantitative and qualitative analysis of chemical constituents in biological fluids · Interpretation of biochemical results in relation to disease states · Understanding of metabolic pathways and their derangements · Application of biochemical principles to patient care Synonyms of Chemical Pathology 1. Clinical Biochemistry 2. Clinical Chemistry 3. Metabolic Medicine 4. Clinical Laboratory Science (in some contexts) 5. Chemical Pathology and Metabolic Medicine 3. INSIGHT INTO EVOLUTION OF CHEMICAL PATHOLOGY The evolution of chemical pathology reflects the broader development of medicine and science, progressing from simple observation to sophisticated molecular analysis. Ancient Period (Pre-18th Century) · Hippocrates (460-377 BC): Described the "four humours" (blood, phlegm, black bile, yellow bile) and their relationship to disease · Galen (129-216 AD): Expanded humoral theory and developed the concept of "urine examination" · Medieval period: "Uroscopy" became a common diagnostic tool, with urine charts describing color, consistency, and sediment The Birth of Clinical Chemistry (18th-19th Century) · 1769: Catherine Macaulay performed the first chemical analysis of urine · 1780: Carl Wilhelm Scheele isolated uric acid from urinary calculi · 1827: Richard Bright correlated proteinuria with kidney disease · 1848: Claude Bernard demonstrated the role of the liver in glucose metabolism · 1850s: Development of gravimetric and volumetric analytical methods · 1880s: Introduction of colorimetric methods for biochemical analysis The Era of Automation (20th Century) Decade Milestone 1920s-1930s Introduction of spectrophotometry 1940s-1950s Development of flame photometry 1960s Introduction of autoanalyzers 1970s Development of radioimmunoassay (RIA) 1980s Introduction of enzyme-linked immunosorbent assay (ELISA), ion-selective electrodes 1990s Automation, computerization, development of point-of-care testing The Molecular Era (21st Century) · Genomics: Genetic testing for inherited metabolic disorders · Proteomics: Protein biomarker discovery · Metabolomics: Comprehensive metabolic profiling · Mass spectrometry: High-throughput, highly specific analysis · Microfluidics: Lab-on-a-chip technologies · Artificial Intelligence: Machine learning for test interpretation and predictive analytics 4. OUTLINE THE SUBSPECIALTIES OF TESTS DONE IN THE CHEMICAL PATHOLOGY LAB The chemical pathology laboratory performs a wide range of subspecialized analyses, organized into distinct sections: A. Routine Clinical Chemistry Basic Metabolic Panel · Glucose (fasting and random) · Blood urea nitrogen (BUN) · Creatinine · Electrolytes (sodium, potassium, chloride) · Bicarbonate · Calcium (total and ionized) · Phosphate · Magnesium Comprehensive Metabolic Panel · All basic metabolic panel components · Liver function tests (ALT, AST, ALP, GGT, bilirubin) · Total protein and albumin · Uric acid B. Endocrinology Thyroid Function Tests · TSH · Free T4 and T3 · Total T4 and T3 · Anti-thyroid antibodies Adrenal Function Tests · Cortisol (plasma and urine) · Aldosterone · Renin · ACTH · Synacthen stimulation tests Pituitary Function Tests · Growth hormone · Prolactin · Gonadotropins (LH, FSH) · Thyroid function (as above) Reproductive Endocrinology · Estradiol · Progesterone · Testosterone · DHEA-S · SHBG Calcium and Bone Metabolism · PTH · Vitamin D (25-OH and 1,25-OH) · Osteocalcin · CTX (bone resorption markers) C. Lipidology · Total cholesterol · HDL cholesterol · LDL cholesterol (calculated and direct) · Triglycerides · Apolipoproteins (Apo A, Apo B, Apo E) · Lipoprotein(a) · Non-HDL cholesterol · Lipid subfractions D. Hepatology · Bilirubin (total, direct, indirect) · Alanine aminotransferase (ALT) · Aspartate aminotransferase (AST) · Alkaline phosphatase (ALP) · Gamma-glutamyl transferase (GGT) · Total protein · Albumin · Ammonia · Coagulation factors (Vitamin K-dependent) E. Nephrology · Urea · Creatinine · Electrolytes · Estimated GFR · Creatinine clearance · Urine protein and albumin · Electrolyte excretion · Osmolality · Urine biochemistry F. Therapeutic Drug Monitoring (TDM) · Digoxin · Aminoglycosides (gentamicin, tobramycin) · Antiepileptics (phenytoin, carbamazepine, valproic acid) · Lithium · Cyclosporin · Theophylline · Vancomycin G. Tumour Markers · Alpha-fetoprotein (AFP) · Carcinoembryonic antigen (CEA) · CA 19-9 · CA 15-3 · CA 125 · PSA (total and free) · Human chorionic gonadotropin (β-HCG) · Prostate-specific antigen H. Trace Elements and Vitamins · Iron studies (iron, ferritin, transferrin, TIBC) · Vitamin B12 · Folate · Vitamin D · Zinc · Copper · Selenium · Heavy metals (lead, mercury, arsenic) I. Specialized Biochemistry · Arterial blood gases · Protein electrophoresis (serum and urine) · HbA1c · Urine porphyrins · Amino acid analysis · Organic acid analysis 5. WHAT ARE PANEL TESTS? DISCUSS THE TWO TYPES WITH EXAMPLES Definition Panel tests (also called "profile tests" or "group tests") are groups of related biochemical investigations that are performed together on a single sample to provide a comprehensive assessment of a particular organ system or metabolic process. These panels are designed to maximize diagnostic yield while minimizing the volume of sample required and the cost of testing. Types of Panel Tests 1. Disease-Specific Panels These panels are designed to investigate particular diseases or clinical presentations. Panel Components Clinical Indication Liver Profile Total bilirubin, conjugated bilirubin, ALT, AST, ALP, GGT, total protein, albumin Suspected liver disease, jaundice Lipid Panel Total cholesterol, triglycerides, HDL-C, LDL-C Cardiovascular risk assessment Bone Profile Calcium, phosphate, ALP, albumin, vitamin D Suspected bone disease, calcium disorders Renal Profile Urea, creatinine, sodium, potassium, chloride, bicarbonate Renal dysfunction assessment Thyroid Profile TSH, free T4, free T3 Thyroid dysfunction assessment 2. Organ-Specific Panels These panels combine tests relevant to a particular organ system. Panel Components Clinical Indication Pancreatic Profile Amylase, lipase, glucose, calcium Acute pancreatitis Cardiac Profile Troponin, CK-MB, BNP, electrolytes Myocardial injury/heart failure Diabetic Profile Glucose, HbA1c, urea, creatinine, lipids Diabetes diagnosis and monitoring Adrenal Profile Cortisol, aldosterone, renin, potassium, sodium Suspected adrenal dysfunction Advantages of Panel Tests 1. Comprehensive assessment: Provides a complete picture of organ function 2. Cost-effective: Bundled pricing often reduces overall cost 3. Convenience: Single sample sufficient for multiple tests 4. Diagnostic synergy: Abnormalities in multiple tests strengthen diagnosis 5. Efficiency: Reduced time for ordering and processing Limitations of Panel Tests 1. Over-testing: May include unnecessary tests 2. False positives: Increased probability of abnormal results by chance 3. Cost: May be more expensive than targeted tests 4. Interpretation challenges: Multiple abnormal results may be confusing 5. Sample requirements: May require larger sample volumes 6. DISCUSS BRIEFLY THE ROLE OF THE PHYSICIAN IN THE PRODUCTION OF VALID LABORATORY RESULTS The physician plays a crucial role in ensuring the validity and clinical utility of laboratory results, from the initial decision to investigate through to the interpretation and application of results. Pre-Analytical Phase A. Appropriate Test Selection · Choosing the right test for the clinical question · Avoiding redundant or unnecessary investigations · Considering cost-effectiveness and clinical utility · Ordering tests with appropriate sensitivity and specificity for the suspected condition B. Proper Test Ordering · Providing complete clinical information to the laboratory · Specifying urgent tests appropriately · Indicating timing (e.g., fasting status, time of day) · Advising patients on test preparation requirements C. Patient Preparation · Ensuring fasting where required (8-12 hours for lipid profiles, 6-8 hours for glucose) · Instructing on medication adjustments when relevant · Explaining the purpose of investigations to patients · Obtaining informed consent where relevant · Ensuring hydration status is adequate D. Specimen Collection · Selecting appropriate specimen types (serum, plasma, urine, etc.) · Ensuring proper collection technique to avoid hemolysis, contamination · Selecting appropriate collection tubes with correct additives · Labeling specimens correctly and completely · Ensuring timely transport to the laboratory Analytical Phase While the physician may not directly perform analyses, they: · Monitor laboratory performance through quality reports · Provide feedback to the laboratory on clinical outcomes · Participate in audit of laboratory utilization · Report adverse events related to laboratory testing Post-Analytical Phase A. Result Interpretation · Understanding normal ranges and their limitations · Recognizing analytical interferences (e.g., hemolysis, lipemia) · Considering physiological variations (age, sex, ethnicity, pregnancy) · Integrating results with clinical context · Evaluating the probability of disease (positive and negative predictive values) B. Clinical Decision-Making · Making diagnoses based on laboratory results · Modifying treatment based on results · Monitoring response to therapy · Recognizing acute emergencies (e.g., critical values) C. Follow-Up · Requesting repeat testing when indicated · Ordering additional investigations based on results · Communicating results to patients appropriately · Documenting clinical decisions and rationale Communication with the Laboratory Physicians must maintain effective communication with the laboratory: · Seeking advice on test interpretation · Reporting unusual findings or suspected interferences · Providing feedback on the clinical utility of tests · Collaborating on research and audit 7. POINT OF CARE TESTS: PRINCIPLES, APPLICATION, ADVANTAGES AND LIMITATIONS Definition Point of Care Testing (POCT) refers to medical diagnostic testing performed at or near the site of patient care. It is also known as near-patient testing, bedside testing, or ancillary testing. POCT enables rapid clinical decisions without the delay associated with central laboratory testing. Principles of POCT POCT devices are designed to be: · Portable: Easily transportable to the patient · Simple: Minimal training required for operation · Rapid: Results available within minutes · User-friendly: Minimal sample preparation · Durable: Robust enough for use in diverse clinical settings Technologies Used in POCT Technology Principles Examples Test strips Chemical reaction with color change Blood glucose, urine dipsticks Biosensors Electrochemical detection of analytes Glucose meters, lactate monitors Immunochromatography Lateral flow immunoassay Pregnancy tests, cardiac markers Microfluidics Miniaturized fluid handling HbA1c, coagulation tests Spectrophotometry Light absorption measurement Hemoglobinometers Electrochemistry Electrical signal proportional to analyte Blood gas analyzers Applications of POCT Emergency and Critical Care · Blood gases (pH, pCO2, pO2, bicarbonate) · Electrolytes (Na, K, Cl) · Glucose (rapid assessment of hypoglycemia/hyperglycemia) · Cardiac markers (troponin for suspected MI) · Coagulation (INR for anticoagulation monitoring) · Lactate (sepsis and shock assessment) Primary and Community Care · Blood glucose (diabetes management) · Urine dipstick (UTI, proteinuria, glucosuria) · Pregnancy testing · Strep A testing · Influenza testing · Malaria rapid diagnostic tests Self-Monitoring · Blood glucose (in diabetes) · International normalized ratio (INR) (in patients on warfarin) · Blood pressure monitoring · Home pregnancy testing Chronic Disease Management · HbA1c · Lipid testing · Renal function (creatinine, urea) · Liver function tests Advantages of POCT Advantage Description Rapid results Clinical decisions within minutes Convenience Testing at the bedside or in community settings Reduced turn-around time No transport to central laboratory Patient satisfaction Quick results, reduced anxiety Improved outcomes Faster clinical intervention Cost-effective Reduced hospital stays, outpatient management Accessibility Testing in remote or resource-limited settings Chronic disease management Facilitates regular monitoring Limitations of POCT Limitation Description Reduced accuracy Generally less precise than central laboratory methods Quality control More difficult to implement and monitor Operator dependence Results affected by operator technique Limited test menu Fewer tests available compared to central laboratory Cost per test Often higher than central laboratory testing Documentation More challenging to integrate with laboratory information systems Training requirements Need for initial and ongoing training Storage and calibration Device maintenance and reagent storage requirements Regulatory compliance Quality assurance and competency assessment 8. PHYSICIAN CONTRIBUTIONS TO VALID LABORATORY RESULTS Pre-Analytical Contributions A. Test Selection and Ordering · Appropriate test selection based on clinical question · Avoiding unnecessary tests (reduces false positives) · Choosing the right timing for specimen collection · Providing complete clinical information to the laboratory · Clear communication of test requirements to patients B. Patient Preparation · Fasting instructions: Ensure appropriate fasting for glucose and lipid profiles · Medication guidance: Advise on withholding interfering medications · Hydration: Ensure adequate hydration to improve venipuncture · Patient positioning: Inform about posture effects on blood constituents · Exercise restrictions: Avoid immediate pre-collection exercise C. Specimen Collection · Proper technique: Minimize hemolysis and tissue contamination · Correct tubes: Use appropriate additive tubes · Correct volume: Ensure adequate sample volume · Aseptic technique: Prevent contamination · Labelling: Complete and accurate patient identification · Storage: Appropriate conditions before transport Analytical Phase Contributions While direct analytical involvement is limited, physicians contribute through: · Feedback to the laboratory: Reporting clinically discordant results · Clinical audits: Evaluating laboratory performance · Quality improvement: Participating in laboratory utilization review · Reporting errors: Identifying and reporting laboratory errors Post-Analytical Contributions A. Result Interpretation · Integration with clinical context: Placing results in the clinical picture · Understanding limitations: Recognizing biological variation · Knowledge of interference: Identifying analytical interferences · Population-specific interpretation: Considering age, sex, ethnicity · Recognizing critical values: Responding immediately to emergency results B. Clinical Decision-Making · Diagnosis: Making or excluding diagnoses · Treatment decisions: Selecting and adjusting therapy · Monitoring: Tracking disease progression or treatment response · Prognosis: Informing patients about likely outcomes C. Communication · Discussing results with patients: Explaining significance · Referring to specialists: When results indicate complex conditions · Documentation: Recording interpretation and actions · Communication with the laboratory: Seeking clarification when needed 9. DISCUSS BRIEFLY THE FACTORS THAT CAN IMPAIR THE VALIDITY OF LABORATORY RESULTS A. Pre-Analytical Factors Patient-Related Factors Factor Effect Age Reference ranges vary with age Sex Hormonal differences affect many analytes Pregnancy Altered physiology affects numerous parameters Fasting status Glucose, lipids affected by fed/fasted state Exercise Creatinine kinase, lactate increase after exercise Time of day Diurnal variation affects cortisol, iron, etc. Posture Orthostatic changes affect protein, calcium Diet Recent meals affect glucose, lipids, triglycerides Medications Numerous drugs affect laboratory tests Alcohol Affects liver function tests, lipids Menstrual cycle Hormonal variations affect reproductive hormones Specimen-Related Factors Factor Effect Hemolysis Intracellular contents released; interferes with many assays Lipemia Optical interference with spectrophotometric assays Icterus (bilirubinemia) Optical interference; affects bilirubin and other assays Incorrect tube Wrong additive affects results (e.g., EDTA with ionized calcium) Inadequate volume Unable to perform requested tests Contamination Extraneous substances affect results Delayed processing Cellular metabolism alters glucose, lactate, ammonia Improper storage Temperature affects analyte stability Improper transport Vibrations, temperature extremes affect sample integrity B. Analytical Factors Factor Effect Methodological issues Assay limitations (interferences, specificity) Calibration errors Systematic bias in results Instrument malfunction Equipment failure affecting results Reagent issues Expired or degraded reagents Quality control failures Unrecognized assay problems Operator errors Human error in analysis Interference Substances affecting the assay (e.g., paraproteins, heterophile antibodies) C. Post-Analytical Factors Factor Effect Transcription errors Misrecording of results Interpretation errors Misunderstanding of reference ranges Communication errors Failure to report critical results Lack of clinical context Misinterpretation without clinical information Inappropriate reference range Using wrong range for patient group D. Biological Factors Factor Effect Biological variation Individual variations within reference ranges Circadian rhythms Daily variations in many analytes Seasonal variations Changes in vitamin D, TSH Menstrual cycle Hormonal variations Genetic factors Individual variations due to genetic polymorphisms 10. PRE-ANALYTICAL CAUSES OF ERRORS IN LABORATORY RESULTS Pre-analytical errors are the most common source of laboratory errors, accounting for 60-70% of all laboratory errors. Patient Preparation Errors A. Fasting Status · Non-fasting samples for glucose, lipids, triglycerides · Prolonged fasting affecting glucose, ketones, bilirubin · Insufficient fasting for glucose tolerance tests B. Diet · Recent high-fat meal causing lipemia · Recent high-protein meal affecting urea · High-sugar meal affecting glucose · Alcohol consumption affecting liver function tests, triglycerides · Caffeine affecting cortisol, glucose C. Medications · Thiazide diuretics: Hyperglycemia, hyperuricemia, hypokalemia · Loop diuretics: Electrolyte disturbances · ACE inhibitors: Hyperkalemia · Steroids: Hyperglycemia, altered cortisol · HRT: Altered lipids, hormone levels · Oral contraceptives: Altered liver function, lipids · Antiepileptics: Altered biochemistry profile · NSAIDs: Renal function effects D. Exercise · Creatinine kinase elevation · Lactate elevation · Potassium elevation · Glucose alteration · Enzyme changes E. Posture · Supine position: Lower protein, calcium, cholesterol · Standing position: Higher protein, calcium, cholesterol · Tourniquet application: Can cause hemoconcentration if prolonged Specimen Collection Errors A. Collection Technique · Hemolysis: Inadequate aseptic technique, needle trauma · Difficult venipuncture: Tissue contamination with thromboplastin · Prolonged tourniquet: Hemoconcentration · Inappropriate site: Capillary samples differ from venous B. Collection Tubes · Wrong additive: Heparin affecting calcium, EDTA affecting ionized calcium, fluoride affecting electrolytes · Wrong order of draw: Cross-contamination of additives · Underfilling tubes: Incorrect blood-to-anticoagulant ratio · Overfilling tubes: Affects anticoagulant concentration C. Specimen Labelling · Misidentification: Wrong patient results · Unlabelled specimens: Inability to process · Incorrect date/time: Misleading historical comparisons Specimen Processing Errors A. Time Factors · Delayed separation: Serum/plasma contact with cells affecting glucose, lactate, potassium, ammonia · Delayed transport: Cellular metabolism affecting analytes · Delayed processing: Analytes degraded B. Temperature · Inadequate cooling: Loss of labile analytes (e.g., ammonia, lactate) · Inadequate warming: Lipemia formation · Extreme temperatures: Protein precipitation C. Centrifugation · Insufficient speed: Incomplete separation · Prolonged centrifugation: Hemolysis · Fibrin clots: Interference with assays D. Storage · Inadequate storage conditions: Analytes degrade · Refreezing samples: Protein precipitation · Prolonged storage: Analytes become unstable Transportation Errors · Excessive vibration: Hemolysis · Extreme temperatures: Analyte degradation · Exposure to light: Bilirubin degradation · Transport medium: Inappropriate containers Documentation Errors · Incomplete request forms: Inadequate clinical information · Wrong patient details: Misidentification · Incorrect test requests: Wrong tests performed · Loss of test requests: Tests not performed 11. SIGNIFICANCE OF THERAPEUTIC DRUG MONITORING IN A PATIENT WITH HEART FAILURE ON DIGOXIN THERAPY Introduction Therapeutic drug monitoring (TDM) is the clinical practice of measuring specific drugs at predetermined intervals to maintain a constant concentration in the blood, optimizing individual dosage regimens. In patients with heart failure on digoxin therapy, TDM is critically important due to the narrow therapeutic index of digoxin and the multiple factors that can affect its pharmacokinetics and pharmacodynamics. Rationale for Digoxin TDM A. Narrow Therapeutic Index Parameter Concentration Therapeutic range 0.8 - 2.0 ng/mL (1.0 - 2.6 nmol/L) Toxic concentration 2.0 ng/mL (> 2.6 nmol/L) Toxicity risk Significant at concentrations > 2.5 ng/mL B. Pharmacokinetic Variability Digoxin has significant inter-individual and intra-individual variability: 1. Absorption · Variable bioavailability (60-80%) · Food effects · Drug interactions 2. Distribution · Lipid solubility · Protein binding (20-30%) · Tissue binding (skeletal muscle, heart) · Volume of distribution affected by: · Obesity · Muscle mass · Cardiac output 3. Metabolism · Minimal hepatic metabolism (only 13%) · Enterohepatic recirculation · Intestinal metabolism 4. Elimination · Renal excretion (60-80% unchanged) · Renal function affected by: · Heart failure (reduced perfusion) · Age-related decline · Drug interactions Factors Affecting Digoxin Levels in Heart Failure A. Renal Dysfunction · Decreased clearance: Impaired renal function prolongs digoxin half-life · Reduced GFR: Less drug excreted, higher levels · Creatinine monitoring: Estimated GFR guides dosing B. Heart Failure State · Reduced cardiac output: Decreased renal perfusion · Congestion: Hepatic congestion affects drug handling · Edema: Volume of distribution changes C. Drug Interactions Drug Mechanism Effect Quinidine Reduces renal clearance; displaces tissue binding Increases digoxin levels (doubles) Amiodarone Reduces renal clearance; reduces distribution volume Increases digoxin levels (50-70%) Calcium channel blockers (verapamil, diltiazem) Reduces renal clearance; reduces P-glycoprotein Increases digoxin levels Spironolactone Reduces renal secretion Increases digoxin levels Potassium-wasting diuretics Hypokalemia Increases toxicity risk Proton pump inhibitors Reduces P-glycoprotein Increases absorption Antibiotics (erythromycin, tetracycline) Reduces intestinal metabolism Increases absorption Furosemide Hypokalemia; may reduce renal clearance Increases toxicity risk D. Electrolyte Disturbances · Hypokalemia (< 3.5 mmol/L): Increases toxicity risk · Hypomagnesemia: Increases toxicity risk · Hypercalcemia: Increases sensitivity · Hyperkalemia: Reduced sensitivity (but may be associated with toxicity) Clinical Significance of Digoxin TDM A. Optimizing Therapeutic Effect Digoxin is used in heart failure primarily to: · Improve cardiac contractility (positive inotropic effect) · Reduce ventricular rate in atrial fibrillation · Improve symptoms (reduced dyspnea, fatigue) TDM ensures: · Therapeutic efficacy: Adequate concentration for clinical response · Minimal toxicity: Avoidance of toxic levels B. Preventing Toxicity Clinical features of digoxin toxicity: Symptoms Signs Nausea, vomiting Cardiac arrhythmias Anorexia Heart block Diarrhea Ventricular tachycardia Blurred vision AV conduction disturbances Yellow/green halos Bradycardia Confusion Atrial tachycardia with block Fatigue - Dizziness - Risk factors for digoxin toxicity: · Renal impairment: Reduced excretion · Hypokalemia: Enhanced toxicity · Hypomagnesemia: Enhanced toxicity · Advanced age: Reduced clearance, reduced muscle mass · Drug interactions: As listed above · Hypothyroidism: Reduced clearance · Heart failure: Reduced clearance C. Guiding Dose Adjustment TDM helps determine: · Starting dose: Based on renal function and body weight · Maintenance dose: Adjusted to achieve therapeutic levels · Frequency of dosing: Daily vs. alternate days · Need for loading dose: In urgent situations Monitoring Strategy A. Timing of Sampling · Steady state: 5-7 days after starting therapy · Trough level: Just before next dose (12 hours after last dose) · Post-distribution: At least 6 hours after oral dose · Sample timing: Consistent timing for comparison B. Frequency of Monitoring Clinical Situation Monitoring Frequency Stable patient Every 6-12 months Initial therapy Every 1-2 weeks until stable Change in renal function According to change Suspected toxicity Immediate Changes in concomitant medication 2-5 days after change Clinical deterioration As clinically indicated C. Interpretation of Results Subtherapeutic levels (< 0.8 ng/mL) · Consider: Non-adherence, reduced absorption, increased clearance · Action: Review compliance, consider dose increase Therapeutic levels (0.8-2.0 ng/mL) · Optimal efficacy: Continue current dose · Monitor: Clinical response, side effects Toxic levels (> 2.0 ng/mL) · Immediate action: Withhold dose · Investigate: Underlying cause, drug interactions, electrolyte disturbances · Treatment: Digoxin-specific antibody fragments (Fab fragments) if severe toxicity Additional Considerations A. Pharmacogenomics Genetic variations affecting: · P-glycoprotein (ABCB1): Affects absorption and clearance · Organic anion transporting polypeptide (OATP): Affects distribution · Renal transporters: Affect elimination B. Alternative Monitoring · ECG monitoring: Early detection of toxicity (heart block, arrhythmias) · Clinical response: Symptom improvement in heart failure · Blood pressure: Avoid hypotension C. Limitations of TDM · No correlation: Not perfectly correlated with clinical effect · Tissue concentration: Serum levels may not reflect tissue concentrations · Mechanism of action: TDM addresses pharmacokinetic variation, not pharmacodynamic variation · Cost: Monitoring adds to healthcare costs Clinical Recommendations 1. Baseline assessment: Renal function (urea, creatinine, eGFR), electrolytes (Na, K, Mg, Ca), weight, age, concurrent medications 2. Start low, go slow: Begin with 125-250 mcg daily based on renal function 3. Monitor at steady state: 5-7 days after starting 4. Adjust for renal function: Use eGFR to guide dosing 5. Monitor electrolytes: Correct hypokalemia and hypomagnesemia 6. Check drug interactions: Review all medications 7. Monitor clinical response: Improvement in symptoms, heart failure stability 8. Watch for toxicity: Educate patient about signs and symptoms 9. Annual monitoring: Check levels annually in stable patients 10. Document: All results and clinical decisions 12. DUTIES OF A PHYSICIAN The duties of a physician encompass clinical, professional, ethical, and administrative responsibilities. Clinical Duties A. Patient Assessment · History taking: Comprehensive medical history · Physical examination: Thorough clinical examination · Differential diagnosis: Formulating diagnostic possibilities · Diagnostic decision-making: Ordering appropriate investigations B. Diagnosis and Treatment · Diagnosis: Reaching a definitive diagnosis · Treatment planning: Developing management strategies · Prescribing: Medications and other interventions · Monitoring: Tracking response to treatment · Referral: Referring to specialists when needed C. Patient Care · Care planning: Developing comprehensive care plans · Preventative care: Promoting health and preventing disease · Chronic disease management: Managing long-term conditions · Palliative care: Providing end-of-life care · Emergency care: Managing acute emergencies Professional Duties · Continuing professional development: Maintaining competence · Evidence-based practice: Applying current best evidence · Audit: Evaluating clinical practice · Quality improvement: Enhancing patient care · Risk management: Minimizing patient harm · Research: Contributing to medic
Tumour Markers
Standard Answer:
1. WHAT ARE TUMOUR MARKERS? Definition Tumour markers (also known as tumour-associated antigens or cancer biomarkers) are substances produced by cancer cells or by the body in response to cancer that can be detected in blood, urine, or tissues. These are biochemical indicators of the presence or activity of a malignant tumour. Characteristics of Tumour Markers Biochemical Nature · Proteins · Glycoproteins · Carbohydrates · Enzymes · Hormones · Genetic material (DNA, RNA) · Other metabolites Production · Tumour cell-produced: Directly by cancer cells · Host-produced: In response to tumour invasion · Ectopic production: Hormones produced by non-endocrine tissues Types of Tumour Markers Category Examples Source Oncofetal antigens AFP, CEA Fetal proteins re-expressed in cancer Tumour-associated antigens CA 125, CA 19-9 Abnormal glycosylation in cancer Enzymes PSA, ALP, NSE Expressed by cancer cells Hormones HCG, ACTH Ectopic production Oncogenes/Suppressor genes HER2, BRCA1, p53 Genetic alterations Metabolic products Catecholamines, 5-HIAA Tumour cell metabolism Clinical Applications Application Description Examples Screening Detecting cancer in asymptomatic individuals PSA (controversial), AFP (for high-risk) Diagnosis Confirming presence of cancer AFP, HCG (germ cell tumours) Prognosis Predicting outcome AFP, HCG, CA 125 Monitoring Tracking response to treatment PSA, CEA, CA 19-9 Surveillance Detecting recurrence PSA, CA 125, CEA Limitations of Tumour Markers · Lack of specificity: Elevated in benign conditions · Lack of sensitivity: Normal levels in some cancers · False positives: Non-cancer conditions cause elevation · Limited role in diagnosis: Usually not diagnostic alone · Stage-dependent: Poor correlation with disease stage · Cross-reactivity: Interference with other substances 2. CLINICAL SITUATIONS WHERE TUMOUR MARKERS HAVE BEEN FOUND USEFUL Most Useful Clinical Situations A. Monitoring Treatment Response Example: PSA in Prostate Cancer · Monitoring: Serial PSA levels to assess response to treatment · Decision-making: Identifying therapeutic failure · Progression: Detecting disease progression Example: CA 125 in Ovarian Cancer · Monitoring: Response to chemotherapy · Recurrence: Early detection of relapse · Prognosis: Correlation with disease burden B. Surveillance for Recurrence Example: CEA in Colorectal Cancer · Post-treatment: Monitoring for disease recurrence · Early detection: Detection before clinical symptoms · Survival: Correlation with prognosis Example: AFP in Hepatocellular Carcinoma · High-risk patients: Screening for recurrence · Detection: Early identification of new lesions C. Diagnosis in Specific Contexts Example: AFP and HCG in Germ Cell Tumours · Diagnosis: Confirmatory in characteristic clinical context · Staging: Correlation with disease extent · Prognosis: Classification of risk Example: PSA with Digital Rectal Examination · Screening: Detection of prostate cancer (controversial) · Diagnosis: Guide to biopsy · Monitoring: Assessing progression D. Prognosis Example: CA 125 in Ovarian Cancer · Initial levels: Predict survival · Response: Early fall predicts better outcome · Residual disease: Correlation with post-surgery Example: AFP and HCG in Testicular Cancer · Staging: International Germ Cell Consensus Classification · Risk: High levels associated with poor prognosis · Response: Normalization indicates favorable outcome E. Guiding Treatment Example: HER2 in Breast Cancer · Treatment: Guiding use of trastuzumab · Prognosis: Marker of aggressive disease · Monitoring: Assessing response to targeted therapy Example: Estrogen Receptor (ER) and Progesterone Receptor (PR) · Treatment: Guiding hormonal therapy · Prognosis: Better prognosis in ER-positive disease · Decision-making: Adjuvant therapy planning Examples of Clinical Situations Clinical Situation Marker Used Clinical Utility Breast cancer (ER/PR) Estrogen receptor, progesterone receptor Guide hormonal therapy; assess prognosis Breast cancer (HER2) HER2 Guide trastuzumab therapy; assess prognosis Prostate cancer PSA Monitor treatment; detect recurrence Colorectal cancer CEA Monitor treatment; detect recurrence Ovarian cancer CA 125 Monitor treatment; detect recurrence Testicular cancer AFP, HCG Diagnose; stage; monitor; prognosticate Hepatocellular carcinoma AFP Screen high-risk; monitor; prognosticate Pancreatic cancer CA 19-9 Monitor treatment; prognosticate Pancreatic neuroendocrine Chromogranin A Diagnose; monitor Multiple myeloma Serum protein electrophoresis, light chains Diagnose; monitor; prognosticate Thyroid cancer Calcitonin Diagnose; monitor medullary thyroid cancer Situations of Greatest Value Situation Markers Clinical Value Germ cell tumours AFP, HCG Highly sensitive, specific; guides treatment Prostate cancer monitoring PSA Sensitive marker for treatment response Ovarian cancer monitoring CA 125 Sensitive for recurrence; guides treatment Breast cancer targeted therapy ER, PR, HER2 Directs specific, effective treatment Colorectal cancer recurrence CEA Useful for early detection 3. WRITE BRIEFLY ON PARANEOPLASTIC SYNDROMES Definition Paraneoplastic syndromes (PNS) are clinical conditions that occur in patients with cancer, caused by the effects of the tumour on the host, but not directly by tumour invasion or metastasis. They are caused by tumour-derived substances (hormones, cytokines) or by the immune response to the tumour cross-reacting with normal tissues. Classification of Paraneoplastic Syndromes A. Endocrine Syndromes Ectopic Hormone Production · Ectopic ACTH: Cushing's syndrome (small cell lung cancer) · Ectopic ADH: Syndrome of Inappropriate ADH (SIADH) (small cell lung cancer) · Ectopic PTHrP: Hypercalcaemia (squamous cell lung cancer, breast, renal) · Ectopic HCG: Hypogonadism, gynecomastia · Ectopic glucagon: Diabetes-like syndrome · Ectopic insulin: Hypoglycaemia B. Neurological Syndromes · Paraneoplastic cerebellar degeneration: Anti-Yo antibodies (breast, ovarian) · Limbic encephalitis: Anti-Hu antibodies (lung) · Lambert-Eaton myasthenic syndrome: VGCC antibodies (small cell lung cancer) · Myasthenia gravis: AchR antibodies (thymoma) · Polymyositis/dermatomyositis: Muscle inflammation · Peripheral neuropathy: Anti-Hu antibodies C. Cutaneous Syndromes · Acanthosis nigricans: Velvety hyperpigmented skin (gastric, lung) · Dermatomyositis: Heliotrope rash, Gottron's papules · Erythema gyratum repens: Gyrate erythematous plaques (lung, breast) · Erythema nodosum: Erythematous nodules (Hodgkin's) · Sweet's syndrome: Acute febrile neutrophilic dermatosis · Trousseau's syndrome: Migratory thrombophlebitis D. Haematological Syndromes · Anaemia: · Anaemia of chronic disease · Haemolytic anaemia (autoimmune) · Pure red cell aplasia (thymoma) · Thrombocytopenia: Autoimmune · Thrombocytosis: Reactive thrombocytosis · Leucocytosis: Paraneoplastic leucocytosis · Coagulopathy: · Disseminated intravascular coagulation (DIC) · Deep vein thrombosis (Trousseau's) · Hyperviscosity syndrome (multiple myeloma) E. Renal Syndromes · Nephrotic syndrome: Membranous glomerulonephritis · Glomerulonephritis: Various types · Acute interstitial nephritis: Drug-related · Tumour lysis syndrome: Acute kidney injury F. Gastrointestinal Syndromes · Malabsorption: Tumour-related · Protein-losing enteropathy: · Intestinal obstruction: Pseudobstruction · Diarrhoea: Secretory diarrhoea (VIPoma) Haematological Syndrome of Paraneoplastic Syndromes Anaemia of Chronic Disease · Mechanism: Cytokine-mediated (IL-6, TNF-α, hepcidin) · Features: Normochromic, normocytic anaemia · Management: Treat underlying cancer Autoimmune Haemolytic Anaemia · Mechanism: Warm antibody type · Features: Positive Coombs test · Association: Chronic lymphocytic leukaemia, lymphoma Thrombocytopenia · Mechanism: Autoimmune thrombocytopenia (ITP-like) · Features: Low platelets, no other haematological abnormality · Association: Lymphoproliferative disorders Thrombocytosis · Mechanism: Reactive due to IL-6, thrombopoietin · Features: Elevated platelets · Association: Many cancers (lung, gastrointestinal) Coagulopathy · DIC: Associated with acute promyelocytic leukaemia · Deep vein thrombosis: Trousseau's syndrome, migratory thrombophlebitis · Hyperviscosity syndrome: Multiple myeloma, Waldenström's Cutaneous Syndrome of Paraneoplastic Syndromes Acanthosis Nigricans · Features: Hyperpigmented, velvety skin (axillae, neck, groin) · Association: Gastric, lung, breast, ovarian cancers · Mechanism: EGF-related Dermatomyositis · Features: Heliotrope rash, Gottron's papules · Association: Various cancers (lung, breast, ovary, gastrointestinal) · Mechanism: Immune-mediated Erythema Gyratum Repens · Features: Wood-grain appearance, rapidly expanding · Association: Lung, breast, oesophageal cancers Erythema Nodosum · Features: Painful erythematous nodules (shins) · Association: Hodgkin's disease, leukaemia Sweet's Syndrome · Features: Acute febrile neutrophilic dermatosis · Association: Haematological malignancies (leukaemia, lymphoma) Gastrointestinal (GI) Syndrome of Paraneoplastic Syndromes Malabsorption · Mechanism: Villous atrophy, intestinal obstruction · Features: Diarrhoea, weight loss, nutritional deficiencies · Association: Various cancers Protein-Losing Enteropathy · Mechanism: Increased intestinal protein loss · Features: Hypoproteinaemia, oedema · Association: Lymphoma, GI cancer Intestinal Pseudo-obstruction · Mechanism: Neuromuscular dysfunction · Features: Constipation, abdominal distension · Association: Small cell lung cancer (anti-Hu antibodies) Secretory Diarrhoea · Mechanism: Ectopic VIP, prostaglandins · Features: Watery diarrhoea, electrolyte disturbances · Association: VIPoma, neuroendocrine tumours Clinical Significance of Paraneoplastic Syndromes · Early diagnosis: May precede cancer detection · Prognosis: Better prognosis if treatable · Treatment: May respond to cancer therapy · Monitoring: Can indicate response or recurrence · Morbidity: Significant in some syndromes 4. EXPLAIN INAPPROPRIATE HORMONE SECRETION AS TUMOUR MARKERS Definition Inappropriate hormone secretion refers to the production of hormones by tumours in tissues that do not normally secrete them. This is called ectopic hormone production, and the hormones produced are called ectopic hormones. This is a type of paraneoplastic syndrome. Mechanism of Ectopic Hormone Secretion Tumours · Derivation: From cells that share a common embryological origin with endocrine cells · Dedifferentiation: Neoplastic transformation leading to expression of genes normally silenced · Autocrine stimulation: Hormones may stimulate their own growth · Amplification: Gene amplification or upregulation of hormone production Types of Ectopic Hormone Secretion Hormone Common Tumours Clinical Syndrome Frequency ACTH Small cell lung cancer (SCLC), carcinoid, thymoma Cushing's syndrome Common (SCLC) ADH Small cell lung cancer, CNS tumours SIADH Common (SCLC) PTHrP Squamous cell lung, breast, renal, head & neck Hypercalcaemia Common HCG Choriocarcinoma, testicular, lung, liver Gynecomastia, precocious puberty Variable Insulin Pancreatic (insulinoma) Hypoglycaemia Rare Glucagon Pancreatic (glucagonoma) Diabetes-like, necrolytic migratory erythema Rare VIP Pancreatic (VIPoma), lung Watery diarrhoea (Verner-Morrison syndrome) Rare Somatostatin Pancreatic (somatostatinoma) Diabetes mellitus, gallstones, steatorrhoea Rare Gastrin Pancreatic (gastrinoma) Zollinger-Ellison syndrome Rare Calcitonin Medullary thyroid cancer Diarrhoea, flushing Variable GH Lung, pancreas Acromegaly Rare Prolactin Lung, kidney Galactorrhoea, amenorrhoea Rare Clinical Examples A. Ectopic ACTH Syndrome Mechanism · Tumours: Small cell lung cancer (most common), carcinoid, thymoma · Hormone: Pro-opiomelanocortin (POMC) processed to ACTH · Clinical features: Rapid onset Cushing's syndrome · Muscle weakness · Weight loss (unlike pituitary Cushing's) · Hypokalaemia · Metabolic alkalosis · Hypertension · Hyperpigmentation Diagnostic Features · Plasma ACTH: High · Cortisol: High (loss of circadian rhythm) · Dexamethasone suppression test: Not suppressed (ectopic) · CRH stimulation test: No response · Imaging: To localize tumour Tumour Markers · Chromogranin A: Neuroendocrine marker · Neuron-specific enolase (NSE): Neuroendocrine marker · CEA: Some lung cancers B. Syndrome of Inappropriate ADH (SIADH) Mechanism · Tumours: Small cell lung cancer (most common) · Hormone: ADH (vasopressin) secreted ectopically · Clinical features: · Hyponatraemia (dilutional) · Hypoosmolality · Urine osmolality > plasma osmolality · High urine sodium · Normal volume status Diagnostic Features · Plasma sodium: Low · Plasma osmolality: Low · Urine osmolality: Inappropriately high · Urine sodium: > 20 mmol/L · Clinical euvolemia Tumour Markers · Chromogranin A: Neuroendocrine marker · NSE: Neuroendocrine marker C. Ectopic PTHrP Syndrome Mechanism · Tumours: Squamous cell lung, breast, renal, head & neck · Hormone: PTH-related peptide (PTHrP) · Clinical features: Hypercalcaemia · Mild symptoms initially · Polyuria, polydipsia · Bone pain · Nephrolithiasis · Pancreatitis · Corneal calcification Diagnostic Features · Serum calcium: High · PTH: Low (suppressed) · PTHrP: High · Phosphate: Low (variable) · ALP: Variable (bone involvement) Tumour Markers · Specific tumour markers: Depending on tumour type Role of Inappropriate Hormone Secretion in Clinical Practice A. Diagnostic Significance · Early cancer detection: May precede clinical symptoms · Screening: Identify tumours with neuroendocrine features · Differentiation: Distinguish between types of hormone-secreting tumours B. Monitoring · Treatment response: Normalization of hormone levels · Recurrence: Rising levels indicate recurrence · Prognosis: High levels may indicate aggressive disease C. Therapeutic Implications · Tumour-directed therapy: Treat underlying cancer · Hormone-directed therapy: Manage endocrine consequences · Targeted therapy: Somatostatin analogues for neuroendocrine tumours Clinical Significance Aspect Significance Diagnosis Unique clinical presentation may guide diagnosis Prognosis May indicate aggressive disease Management Requires multi-disciplinary care (oncology and endocrinology) Monitoring Useful for following treatment response 5. CARCINOEMBRYONIC ANTIGEN (CEA) Introduction Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, normally expressed during fetal development. It was first discovered in 1965 by Gold and Freedman in colonic cancer tissue. CEA is one of the most widely used tumour markers, although its use has diminished with the development of more specific markers. Structure and Function Biochemical Nature · Molecular weight: ~180 kDa · Type: Cell surface glycoprotein · Structure: Belongs to the immunoglobulin superfamily · Function: Cell adhesion molecule Normal Expression · Fetal development: Expressed in fetal tissues (gastrointestinal, liver, pancreas) · Postnatal: Expression is downregulated · Adult expression: Low levels in normal tissues (colon, stomach, lung) Clinical Utility A. Diagnostic Applications Detection of Tumours · Colorectal cancer: Most associated · Other cancers: · Lung cancer · Breast cancer · Gastric cancer · Pancreatic cancer · Ovarian cancer · Hepatocellular carcinoma · Medullary thyroid cancer Limitations · Low sensitivity: Not useful for screening · Lack of specificity: Elevated in benign conditions · Stage-related: Levels correlate with stage B. Monitoring Treatment Response Primary Use · Colorectal cancer: Monitoring after curative resection · Serial measurement: Essential for interpretation · Time to change: < 3 months after treatment Clinical Decision Making · Rising levels: Suggest recurrence · Falling levels: Response to treatment · Persistent elevation: Residual disease C. Surveillance for Recurrence Post-Treatment Monitoring · Colorectal cancer: Every 3-6 months for 2 years · Other cancers: As clinically indicated Detection of Recurrence · Lead time: 2-6 months before clinical symptoms · Sensitivity: ~70% for recurrence · Specificity: May be affected by benign conditions Causes of Elevated CEA A. Malignant Conditions Cancer Type Elevation Frequency Colorectal cancer 70-90% (metastatic) Pancreatic cancer 50-70% Gastric cancer 40-60% Lung cancer 40-60% Breast cancer 30-50% Ovarian cancer 25-40% B. Non-Malignant Conditions Condition Mechanism Smoking Increased production Chronic liver disease Reduced clearance Inflammatory bowel disease Increased production Pancreatitis Increased production Pulmonary infections Increased production Pregnancy Fetal expression Clinical Interpretation A. Reference Range · Normal: < 5 ng/mL (non-smokers) · Normal: < 10 ng/mL (smokers) · Elevated: > 5 ng/mL or > 10 ng/mL B. Factors Affecting Levels Factor Effect Smoking Elevates levels (2-3 times normal) Age May increase with age Race Some ethnic variations Pregnancy Increased Benign conditions Elevated (as above) C. Clinical Decision-Making Monitoring Strategy 1. Baseline: Before surgery/treatment 2. Post-treatment: 2-4 weeks after intervention 3. Follow-up: Every 3-6 months 4. Trend analysis: Serial measurements essential Interpretation Algorithm · Persistent elevation: Residual disease · Rising > 50%: Suggest recurrence · Falling: Response to treatment · Negative: Good response Clinical Limitations Limitation Implication Lack of sensitivity Not for screening Lack of specificity False positives common Variability Multiple factors affect levels Lead time Clinical correlation needed Cost-effectiveness Limited value Recommendations Clinical Scenario Recommendation Diagnosis Not recommended Screening Not recommended Prognosis Limited value Monitoring therapy Recommended for colorectal cancer Surveillance Recommended for colorectal cancer Staging Limited value 6. PROSTATE SPECIFIC ANTIGEN (PSA) Introduction Prostate-specific antigen (PSA) is a serine protease (kallikrein-related peptidase 3) produced by prostate epithelial cells. It is the most extensively used tumour marker for prostate cancer, though its use remains controversial in some contexts. Structure and Function Biochemical Nature · Molecular weight: ~33 kDa · Type: Glycoprotein · Function: Liquefies seminal fluid after ejaculation · Class: Serine protease (kallikrein family) Physiology · Production: Prostate epithelial cells · Forms: Free (tPSA) and bound (cPSA) · Bound forms: Complexed with α1-antichymotrypsin, α2-macroglobulin · Free forms: Inactive, unbound · Prostate-specific: Not specific for prostate cancer Types of PSA Type Description Clinical Utility Total PSA (tPSA) Sum of free and complexed General screening, monitoring Free PSA (fPSA) Unbound PSA Improve specificity, reduce biopsies Complexed PSA (cPSA) Bound to inhibitors Monitoring, specificity PSA velocity Rate of change Assess risk, aggressive cancer PSA density PSA divided by prostate volume Differentiate cancer from BPH PSA doubling time Time to double PSA Prognosis, risk assessment Clinical Utility A. Screening Primary Use · Population-based: Controversial · Individual-based: With informed decision-making Benefits · Early detection: Identifies cancer earlier · Stage migration: More localized disease · Survival: Potential mortality reduction Risks · Overdiagnosis: Clinically insignificant cancers · Overtreatment: Unnecessary interventions · False positives: Anxiety, unnecessary biopsies · Complications: From biopsies Recommendations · USPSTF: Grade C (individualized) · European guidelines: Risk-stratified · American Urological Association: Individualized · British guidelines: Not recommended for population screening B. Diagnosis Detection of Prostate Cancer · Elevated levels: Indicate cancer risk · Threshold: 4.0 ng/mL (traditional), but age-adjusted ranges exist · Diagnosis confirmed by biopsy: Not diagnostic alone Indications for Biopsy · PSA > 4.0 ng/mL: Significant elevation · PSA velocity > 0.75 ng/mL/year: Rapid increase · Abnormal DRE: Palpable nodule · High-risk factors: Family history, ethnicity C. Staging and Prognosis Correlation with Disease · Localized disease: Low PSA · Locally advanced: Moderate elevation · Metastatic disease: High PSA (> 20 ng/mL) · Aggressive disease: Rapidly rising levels Risk Stratification · Low risk: PSA < 10, Gleason ≤ 6 · Intermediate risk: PSA 10-20, Gleason 7 · High risk: PSA > 20, Gleason ≥ 8 D. Monitoring Treatment Post-Treatment Follow-up · Radical prostatectomy: PSA should be undetectable · Radiotherapy: Nadir followed by slow rise · Hormone therapy: Monitor response Detection of Recurrence · Rising PSA: Biochemical recurrence · Define: PSA > 0.2 ng/mL after prostatectomy · Lead time: 6-12 months before clinical progression Interpretation of PSA Results A. Reference Range Age Group Normal Range (ng/mL) 40-49 years 0.0-2.5 50-59 years 0.0-3.5 60-69 years 0.0-4.5 70-79 years 0.0-6.5 80+ years 0.0-8.0 B. Factors Affecting PSA Factor Effect Age Increases with age Race Higher in African-Americans BPH Increased (2-3 times) Prostatitis Marked increase (acute) Digital rectal examination Minimal increase (transient) Ejaculation Minimal increase (transient) Urinary tract infection Increased Previous biopsy Increased (1-2 weeks) Urinary retention Increased Prostate massage Increased (transient) Special Considerations A. PSA in Prostate Cancer Management Clinical Scenario PSA Role Interpretation Initial diagnosis Screening, biopsy guidance Evaluate risk Staging Risk stratification Combine with Gleason Post-prostatectomy Detect recurrence Undetectable = cured Post-radiotherapy Monitor response Nadir then rise On hormone therapy Monitor response Suppressed levels B. False Positives and False Negatives False Positives · Elevated PSA: Without cancer · Most common: BPH (50-70%) · Other: Prostatitis, UTI · Management: Use fPSA, repeat testing, imaging False Negatives · Normal PSA: With cancer · Most common: Low-grade cancer · Management: Consider free PSA, density, velocity Clinical Applications Summary Application Utility Limitations Screening Controversial Overdiagnosis Diagnosis Biopsy decision Not diagnostic alone Prognosis Risk stratification Gleason score important Monitoring Excellent Multiple factors Recurrence Sensitive Need clinical context 7. FEATURES AND TYPES OF TUMOUR MARKERS Features of Tumour Markers A. General Characteristics Biochemical Features · Proteins: Most common · Glycoproteins: Many markers · Carbohydrates: CA series · Enzymes: Some markers · Hormones: Ectopic production · Genetic material: DNA, RNA Clinical Features · Non-invasive: Detected in body fluids · Quantitative: Can be serially measured · Interpretable: Requires understanding of limitations · Cancer association: Not always specific B. Ideal Tumour Marker Characteristics Characteristic Description Sensitivity Detect cancer early, minimize false negatives Specificity Only elevated in cancer, minimize false positives Organ specificity Localize tumour origin Quantitative Correlate with tumour burden Non-invasive Easily accessible sample Cost-effective Affordable for clinical use Reproducible Consistent results Predictive Guide treatment decisions Prognostic Predict outcome Types of Tumour Markers A. By Source of Production 1. Tumour Cell-Produced Markers · Oncofetal antigens: AFP, CEA · Tumour-associated antigens: CA 15-3, CA 19-9, CA 125 · Oncogene products: HER2, RAS · Enzymes: PSA, ALP, NSE · Hormones: HCG, ACTH 2. Host Response Markers · Antibodies: Anti-p53, anti-Hu · Cytokines: Interleukins, growth factors · Acute phase proteins: CRP, serum amyloid A 3. Cellular/Biochemical Markers · Hormone receptors: ER, PR · Metabolic products: Catecholamines, 5-HIAA · Genetic markers: DNA mutations, RNA expression B. By Clinical Application Category Examples Primary Use Screening markers PSA, AFP, CA 125 Population-based screening Diagnostic markers AFP, HCG, PSA Confirmatory testing Prognostic markers AFP, HCG, CA 125 Predict outcome Monitoring markers PSA, CEA, CA 125 Treatment follow-up Predictive markers ER, PR, HER2 Guide therapy choice C. By Tumour Type Tumour Type Markers Breast cancer CA 15-3, CA 27.29, ER, PR, HER2, CEA Colorectal cancer CEA, CA 19-9, KRAS Prostate cancer PSA, free PSA, PSMA Ovarian cancer CA 125, HE4 Pancreatic cancer CA 19-9, CEA Lung cancer NSE, CEA, CYFRA 21-1 Germ cell tumours AFP, HCG, LDH Hepatocellular cancer AFP Neuroendocrine tumours Chromogranin A, NSE, 5-HIAA Examples of Major Tumour Markers Marker Molecular Type Associated Cancers Clinical Utility AFP Glycoprotein HCC, germ cell tumours Diagnosis, monitoring, prognosis CA 125 Glycoprotein Ovarian cancer Monitoring, recurrence detection CA 19-9 Carbohydrate Pancreatic, biliary, gastric Monitoring, prognosis CA 15-3 Glycoprotein Breast cancer Monitoring CEA Glycoprotein Colorectal, lung, breast Monitoring, recurrence PSA Serine protease Prostate cancer Screening, monitoring HCG Glycoprotein Germ cell, trophoblastic Diagnosis, monitoring HER2 Growth factor receptor Breast, gastric, ovarian Prognosis, targeted therapy ER/PR Hormone receptors Breast cancer Prognosis, endocrine therapy NSE Enzyme Neuroendocrine, small cell lung Diagnosis, monitoring 8. USES AND PROPERTIES OF AN IDEAL TUMOUR MARKER Properties of an Ideal Tumour Marker A. Analytical Properties Property Description Significance High sensitivity Detect low levels of cancer Early detection possible High specificity Only elevated in cancer Minimize false positives Organ/tumour specificity Localize to specific cancer Guide investigation Quantitative assay Reliable measurement Monitor progression Reproducible Consistent results Reliable interpretation Pre-analytical stability Stable sample Practical clinical use Cost-effective Affordable assay Widespread use B. Clinical Properties Property Description Significance Early detection Detect preclinical disease Improved outcomes Correlation with stage Increased with progression Prognostic value Correlation with burden Reflect tumour mass Monitor therapy Short half-life Rapid decline after treatment Assess response Predictive value Guide therapy Personalized medicine Prognostic value Predict outcome Clinical decision-making Non-invasive Easily accessible Patient acceptance Uses of Tumour Markers A. Screening Purpose · Population screening: Detect cancer in asymptomatic individuals · High-risk screening: Targeted at high-risk groups · Pre-cancer detection: Identify early lesions Examples · PSA: Prostate cancer (controversial) · AFP: Hepatocellular carcinoma (high-risk patients) · CEA: Not recommended for screening · CA 125: Not recommended for population screening Criteria for Screening Programmes · High prevalence: Disease common in population · Effective treatment: Available with better outcomes at early stage · Acceptable morbidity: Benefits outweigh risks · Cost-effective: Affordable for the healthcare system B. Diagnosis Purpose · Support diagnosis: Provide evidence for cancer · Confirmation: Confirm suspected diagnosis · Differentiation: Distinguish from benign conditions · Guidance: Direct further investigations Examples · AFP/HCG: Germ cell tumours · PSA: Prostate cancer (with DRE) · CA 125: Ovarian cancer (with imaging) Limitations · Not diagnostic alone: Requires histological confirmation · False positives: Benign conditions · False negatives: Some cancers not producing marker C. Staging and Prognosis Purpose · Risk stratification: Categorize patients · Prognosis: Estimate outcome · Treatment selection: Guide therapy intensity · Decision-making: Informing clinical decisions Examples · AFP/HCG: Germ cell tumour staging · PSA: Prostate cancer risk stratification · CA 125: Ovarian cancer prognosis Prognostic Markers · AFP: Correlates with tumour burden · HCG: Correlates with tumour burden · PSA: Correlates with disease extent D. Monitoring Treatment Purpose · Assess response: Evaluate effectiveness · Detect progression: Identify treatment failure · Guide continuation: Decide when to stop · Modify therapy: Adjust based on response Examples · PSA: Prostate cancer response · CEA: Colorectal cancer response · CA 125: Ovarian cancer response Monitoring Principles · Baseline: Before treatment · Serial measurement: Regular intervals · Trend analysis: Evaluate direction · Clinical correlation: Integrate with other factors E. Surveillance for Recurrence Purpose · Early detection: Identify relapse · Guide imaging: Direct investigations · Prognosis: Assess outcome Examples · PSA: Prostate cancer · CEA: Colorectal cancer · CA 125: Ovarian cancer Follow-up Schedule · Initial: Every 3-6 months for first 2 years · Later: Every 6-12 months for years 2-5 · Long-term: Annually after 5 years Clinical Decision-Making with Tumour Markers Clinical Scenario Markers Used Interpretation Screening PSA, AFP Elevated = high risk Diagnosis AFP, HCG, PSA Support diagnosis Staging Multiple markers Correlate with stage Monitoring therapy Serial markers Trend evaluation Surveillance Serial markers Rising = recurrence Clinical Limitations of Tumour Markers Limitation Impact Lack of sensitivity Some cancers do not produce markers Lack of specificity Elevated in benign conditions False positives Leads to unnecessary investigations False negatives Delayed diagnosis Cost Financial burden Patient anxiety Psychological impact Inadequate predictive value Limited clinical utility
Acid-Base Disorders
Standard Answer:
1. COMPENSATORY MECHANISMS AND SYSTEMIC EFFECTS OF RESPIRATORY ACIDOSIS Definition Respiratory acidosis is a primary acid-base disorder characterized by increased arterial pCO■ (> 45 mmHg) leading to a decrease in arterial pH (< 7.35). It results from alveolar hypoventilation, leading to CO■ retention. Pathophysiology Mechanism · Alveolar hypoventilation: Reduced minute ventilation · CO■ retention: Increased pCO■ · Acidosis: Increased hydrogen ion concentration · Hypercapnia: Elevated CO■ levels Causes of Respiratory Acidosis Category Examples Central nervous system depression Drugs (sedatives, opioids), stroke, trauma, tumours Neuromuscular disease Guillain-Barré syndrome, myasthenia gravis, ALS, botulism Thoracic cage abnormalities Flail chest, kyphoscoliosis, fibrothorax Airway obstruction Asthma, COPD, foreign body, tumor Pulmonary disease Pneumonia, pulmonary edema, interstitial lung disease Sleep-disordered breathing Obstructive sleep apnoea, central sleep apnoea Inadequate ventilation Mechanical ventilation settings Compensatory Mechanisms A. Acute Compensation Chemical Buffering · Immediate: Occurs within minutes · Plasma proteins: Main buffer · Haemoglobin: Important buffer · Bicarbonate: Limited acute role · Effect: Partial buffering, limited efficacy Physiological Changes · Increased renal H■ excretion: Limited acute effect · Increased renal bicarbonate reabsorption: Limited acute effect · Shift of H■ into cells: Exchange with K■ · Transcellular shifts: H■/K■ exchange B. Chronic Compensation Renal Compensation · Mechanism: Increased H■ secretion · H■ excretion: Increased excretion of titratable acids · Bicarbonate reclamation: Increased reabsorption · Ammoniagenesis: Increased production of ammonia · Duration: Days to weeks Expected Changes · Acute respiratory acidosis: HCO■■ increases by 1 mEq/L for each 10 mmHg increase in pCO■ · Chronic respiratory acidosis: HCO■■ increases by 3-4 mEq/L for each 10 mmHg increase in pCO■ Compensatory Response HCO■■ Change Acute ∆HCO■■ = 0.1 × (∆pCO■) Chronic ∆HCO■■ = 0.3-0.4 × (∆pCO■) Renal Mechanisms 1. Proximal tubule: Reclamation of filtered HCO■■ 2. Distal tubule: Excretion of titratable acids (H■ + phosphate) 3. Collecting duct: Excretion of ammonium (NH■■) Systemic Effects A. Cardiovascular Effects Effect Mechanism Vasodilatation Direct vasodilatory effect of CO■ Increased cardiac output Sympathetic stimulation Tachycardia Sympathetic response Cardiac arrhythmias Hyperkalemia, acidosis effects Decreased myocardial contractility Acidosis effect Peripheral vasodilatation CO■ vasodilatory effect Pulmonary vasoconstriction Direct effect of acidosis Pulmonary hypertension Vasoconstriction, hypoxic response B. Neurological Effects Effect Mechanism Cerebral vasodilatation CO■ vasodilatory effect Increased intracranial pressure Vasodilatation Headache Vasodilatation, increased pressure Confusion Central nervous system depression Drowsiness Progressive CO■ narcosis Coma Severe hypercapnia Papilloedema Increased intracranial pressure Seizures Acidosis, electrolyte disturbances C. Respiratory Effects Effect Mechanism Tachypnoea Compensatory response Dyspnoea Hypoxia, acidosis Cyanosis Hypoxia Flapping tremor Hepatic encephalopathy-like Impaired ventilation Pre-existing condition D. Renal Effects Effect Mechanism Increased H■ excretion Compensatory Increased bicarbonate reclamation Compensatory Potassium shift H■/K■ exchange Hypokalaemia Transcellular shift Hypercalciuria Acidosis effect E. Metabolic Effects Effect Mechanism Hyperkalemia Transcellular shift Hypocalcaemia Acidosis effect on calcium binding Hypercalciuria Bone demineralization Increased lactate Tissue hypoxia Increased ammonia Renal compensation Deranged glucose metabolism Acidosis effect F. Haematological Effects Effect Mechanism Right shift of oxygen dissociation curve Bohr effect Decreased oxygen affinity Reduced affinity for O■ Polycythaemia Chronic hypoxia Increased erythropoietin Hypoxia stimulation Hypercoagulability Acidosis effect Clinical Management Principles of Management 1. Treat underlying cause: Address the primary ventilatory problem 2. Improve ventilation: Bronchodilators, steroids, oxygen 3. Respiratory support: Non-invasive or invasive ventilation 4. Correct electrolytes: Potassium, calcium 5. Monitor response: Serial blood gases Specific Considerations · COPD: Controlled oxygen therapy · Asthma: Bronchodilators, steroids · Neuromuscular disease: Respiratory support · Drug overdose: Reversal agents · Sleep apnoea: CPAP, BiPAP Complications Complication Mechanism Pulmonary hypertension Hypoxic vasoconstriction Cor pulmonale Chronic right heart strain Cardiac arrest Severe acidosis, arrhythmias Seizures Acidosis, electrolyte disturbances Coma CO■ narcosis Death Uncorrected respiratory failure 2. BICARBONATE GENERATION AT THE LEVEL OF THE KIDNEY, RED BLOOD CELL, AND STOMACH Introduction Bicarbonate (HCO■■) generation is essential for maintaining acid-base homeostasis. Different organs contribute to bicarbonate synthesis through distinct mechanisms, primarily involving the conversion of CO■ and water to H■ and HCO■■, catalyzed by carbonic anhydrase. Bicarbonate Generation in the Kidney A. Mechanism Proximal Tubule · Carbonic anhydrase activity: In luminal membrane · H■ secretion: Na■/H■ exchange (NHE3) · HCO■■ reclamation: Reabsorption of filtered bicarbonate · Net effect: Regenerates bicarbonate, maintains acid-base balance Distal Tubule and Collecting Duct · H■ secretion: H■-ATPase, H■/K■-ATPase · HCO■■ generation: Intracellular carbonic anhydrase · Ammoniagenesis: Production of NH■ for excretion B. Key Enzymes Enzyme Location Function Carbonic anhydrase (CA) Tubular cells CO■ + H■O ↔ H■CO■ Glutaminase Proximal tubule Glutamine → NH■■ + HCO■■ Na■/H■ exchanger (NHE) Apical membrane H■ secretion, Na■ reabsorption H■-ATPase Distal tubule H■ secretion C. Phases of Bicarbonate Generation 1. Bicarbonate Reclamation (Filtered Bicarbonate) · Mechanism: Reabsorption of filtered HCO■■ · Location: Proximal tubule (~85%) · Process: H■ secretion combines with HCO■■ → H■CO■ → CO■ + H■O · Net effect: Preserves filtered bicarbonate 2. Bicarbonate Regeneration (Net Acid Excretion) · Mechanism: Formation of new HCO■■ · Location: Distal tubule, collecting duct · Process: Glutamine metabolism → NH■■ + HCO■■ · Net effect: Generates new bicarbonate equivalent to acid excreted D. Regulation of Renal Bicarbonate Generation Stimulus Effect Mechanism Metabolic acidosis Increased generation Increased ammoniagenesis Hypokalaemia Increased generation Enhanced NH■■ excretion Aldosterone Increased generation Stimulates H■ secretion Parathyroid hormone Decreased generation Inhibits proximal HCO■■ reabsorption Angiotensin II Increased generation Stimulates Na■/H■ exchange Bicarbonate Generation in Red Blood Cells A. Mechanism In Red Blood Cells · Carbonic anhydrase: High activity in erythrocytes · Reaction: CO■ + H■O ↔ H■CO■ ↔ H■ + HCO■■ · Net effect: Formation of bicarbonate from CO■ Chloride Shift (Hamburger Phenomenon) · Process: HCO■■ exits cell, Cl■ enters to maintain charge balance · Direction: HCO■■ from RBC → plasma · Consequence: Exports HCO■■ to plasma, maintains plasma pH B. Key Enzymes Enzyme Location Function Carbonic anhydrase RBC cytoplasm CO■ hydration/dehydration Band 3 protein (AE1) RBC membrane Cl■/HCO■■ exchange C. Clinical Significance · CO■ transport: ~70% of CO■ transported as HCO■■ in plasma · Acid-base balance: Immediate buffering capacity · Role: First-line defense against acid-base disturbances · Sensitivity: Functional impairment affects acid-base homeostasis Bicarbonate Generation in the Stomach A. Mechanism Gastric Parietal Cells · CO■ hydration: CO■ + H■O → H■CO■ → H■ + HCO■■ · H■ secretion: H■/K■-ATPase (proton pump) · HCO■■ movement: Enters blood ("alkaline tide") Net Effect · Stomach lumen: Acid (HCl) · Blood: Alkaline (HCO■■) · Balance: One H■ secreted = one HCO■■ generated B. Key Enzymes Enzyme Location Function Carbonic anhydrase Parietal cell CO■ + H■O ↔ H■CO■ H■/K■-ATPase Apical membrane Active H■ secretion C. Clinical Significance Alkaline Tide · Phenomenon: Post-prandial bicarbonate generation · Effect: Short-lived increase in plasma HCO■■ · Implications: Transient acid-base changes Gastric Acid Secretion · Volume: ~2 L/day of gastric juice · Acid content: ~100 mEq/L · Bicarbonate generated: Corresponding amount Comparison of Bicarbonate Generation Mechanisms Organ Primary Role Mechanism Enzyme Clinical Significance Kidney Acid-base regulation Excrete H■, generate HCO■■ CA, glutaminase Maintains chronic acid-base balance RBC CO■ transport CO■ → HCO■■ CA Immediate buffering, CO■ transport Stomach Digestive acid secretion H■ secretion, HCO■■ to blood CA, H■/K■-ATPase Post-prandial alkaline tide Clinical Implications Condition Effect on Bicarbonate Metabolic acidosis Increased renal generation Metabolic alkalosis Decreased renal generation Hypokalaemia Increased renal generation Hyperkalaemia Decreased renal generation Respiratory acidosis Increased renal generation (chronic) Respiratory alkalosis Decreased renal generation (chronic) 3. BICARBONATE RECLAMATION Definition Bicarbonate reclamation refers to the process by which the kidney reabsorbs filtered bicarbonate from the glomerular filtrate back into the blood. This is essential for maintaining plasma bicarbonate levels and acid-base homeostasis. Physiology of Bicarbonate Reclamation A. Overview Filtered Load · Normal GFR: ~120 mL/min · Plasma HCO■■: ~24 mEq/L · Filtered HCO■■: ~2,880 mEq/day (24 × 120 × 1440 min/day) Reabsorption · Proximal tubule: ~85% of filtered load · Loop of Henle: ~10% (thick ascending limb) · Distal tubule: ~5% · Collecting duct: ~1% Net Result · All filtered HCO■■ reabsorbed: Maintaining plasma levels · Threshold: Minimal urinary HCO■■ B. Mechanisms of Bicarbonate Reclamation Proximal Tubule (85% of Reclamation) Luminal Membrane 1. Na■/H■ exchange (NHE3): Secretes H■ into lumen 2. H■ combines with HCO■■: → H■CO■ 3. Carbonic anhydrase (CA): H■CO■ → H■O + CO■ 4. CO■ diffuses into cell: Along concentration gradient Intracellular 1. CO■ + H■O: CA → H■CO■ 2. H■CO■: → H■ + HCO■■ 3. H■: Recycled for NHE3 4. HCO■■: Across basolateral membrane (Na■/HCO■■ cotransporter, NBC1) Loop of Henle (10% of Reclamation) · Thick ascending limb: Na■/HCO■■ cotransport · Mechanism: Secondary active transport · Regulation: Influenced by acid-base status Distal Tubule (5% of Reclamation) · Distal convoluted tubule: H■ secretion via H■-ATPase · Collecting duct: H■ secretion via H■-ATPase and H■/K■-ATPase C. Regulation of Bicarbonate Reclamation Factor Effect Mechanism Acidosis Increased reclamation Stimulates Na■/H■ exchange Alkalosis Decreased reclamation Inhibits Na■/H■ exchange Angiotensin II Increased reclamation Stimulates NHE3 Aldosterone Increased reclamation Stimulates Na■/H■ exchange PTH Decreased reclamation Inhibits Na■/HCO■■ cotransport Volume contraction Increased reclamation Increased NHE3 activity Volume expansion Decreased reclamation Decreased NHE3 activity Clinical Significance A. Bicarbonate Reabsorption Disorders Proximal Renal Tubular Acidosis (Type 2 RTA) · Defect: Impaired proximal HCO■■ reabsorption · Features: · Low serum HCO■■ · Urine pH > 5.5 (during HCO■■ loading) · Low fractional HCO■■ excretion · Causes: Fanconi syndrome, myeloma, drugs Normal Physiology · Urine pH: Acidic (< 5.5) · HCO■■ excretion: < 1% of filtered load · Serum HCO■■: Normal (22-28 mEq/L) B. Drugs Affecting Bicarbonate Reclamation Drug Effect Mechanism Acetazolamide Decreased reclamation Carbonic anhydrase inhibitor Thiazides Mild decrease Volume contraction Loop diuretics Mild decrease Volume contraction Amiloride Decreased reclamation Na■/H■ exchanger inhibitor Assessment of Bicarbonate Reclamation A. Clinical Tests Urine pH · Measurement: Indicator of H■ secretion · Interpretation: pH < 5.5 indicates adequate H■ secretion · Limitation: Affected by diet, drugs Fractional Excretion of Bicarbonate (FEHCO■) · Formula: (Urine HCO■■ × Plasma Creatinine)/(Plasma HCO■■ × Urine Creatinine) × 100 · Normal: < 1% · Interpretation: > 5% indicates proximal tubular defect Urine Anion Gap · Formula: Na■ + K■ - Cl■ (urine) · Normal: 0-10 mEq/L · Negative anion gap: Suggests impaired NH■■ excretion B. Clinical Interpretation Condition Urine pH FEHCO■ Interpretation Normal < 5.5 < 1% Normal reclamation Type 2 RTA 5.5 5% Impaired reclamation Type 1 RTA 5.5 < 5% Impaired acidification Type 4 RTA 5.5 < 5% Aldosterone deficiency Clinical Consequences of Impaired Bicarbonate Reclamation Consequence Mechanism Metabolic acidosis Loss of bicarbonate Growth retardation Acidosis effect Osteomalacia Bone buffering Nephrolithiasis Hypercalciuria Muscle weakness Acidosis effect 4. METABOLIC ACIDOSIS – LIST 5 COMMON CAUSES Definition Metabolic acidosis is a primary acid-base disorder characterized by a decrease in plasma bicarbonate (< 22 mEq/L) and arterial pH (< 7.35), resulting from either: 1. Increased production of organic acids (e.g., ketoacids, lactic acid) 2. Loss of bicarbonate (e.g., diarrhoea) 3. Impaired renal acid excretion (e.g., renal tubular acidosis) 4. Ingestion of acids (e.g., salicylates, methanol) Classification A. Anion Gap Metabolic Acidosis (High Anion Gap) Pathogenesis: Accumulation of unmeasured anions Normal Anion Gap: Na■ - (Cl■ + HCO■■) = 10-20 mEq/L Causes of High Anion Gap Metabolic Acidosis (MUDPILES) Causes Mechanism Methanol Formic acid (by-product) Uraemia Organic acids retention Diabetic ketoacidosis Ketone bodies (acetoacetate, β-hydroxybutyrate) Paraldehyde Organic acids accumulation Iron/Inborn errors Acid accumulation Lactic acidosis Lactic acid (type A and B) Ethanol Ketones, lactic acid Salicylates Salicylic acid B. Normal Anion Gap Metabolic Acidosis Pathogenesis: Loss of bicarbonate or impaired H■ excretion Causes of Normal Anion Gap Metabolic Acidosis Causes Mechanism Diarrhoea Bicarbonate loss (GI) Renal tubular acidosis Impaired H■ excretion Pancreatic drainage Bicarbonate loss Acetazolamide Carbonic anhydrase inhibition Urinary diversion Bicarbonate loss Five Common Causes of Metabolic Acidosis 1. Diabetic Ketoacidosis (DKA) Pathophysiology · Insulin deficiency: Relative or absolute · Counterregulatory hormones: Glucagon, catecholamines, growth hormone, cortisol · Lipolysis: Free fatty acid release · Ketogenesis: Ketone bodies (acetoacetate, β-hydroxybutyrate, acetone) · Acidosis: Ketone bodies accumulate Clinical Features · Hyperglycemia: Glucose > 250 mg/dL (> 13.9 mmol/L) · Ketonemia: Elevated ketone bodies · Acidosis: pH < 7.30, bicarbonate < 18 mEq/L · Symptoms: Polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain · Signs: Kussmaul respirations, fruity breath (acetone), dehydration Diagnosis · Glucose: High · Ketones: Positive (serum and urine) · pH: Low · Anion gap: High (Na■ - (Cl■ + HCO■■) > 12) Management · Fluid replacement: Isotonic saline · Insulin: Intravenous infusion · Potassium: Replacement · Monitor: Glucose, electrolytes, acid-base status 2. Lactic Acidosis Pathophysiology · Type A (hypoxic): Tissue hypoxia (shock, sepsis, cardiac arrest) · Type B (non-hypoxic): Liver disease, diabetes, malignancy, drugs · Lactate production: Anaerobic glycolysis · Acidosis: Lactic acid accumulation Causes · Shock: Septic, hypovolaemic, cardiogenic · Severe anaemia: Tissue hypoxia · Liver disease: Impaired lactate clearance · Drugs: Metformin (rarely), alcohol, isoniazid · Malignancy: Lymphoma, leukaemia · Infections: Sepsis Clinical Features · Severe acidosis: pH < 7.2, bicarbonate < 10 mEq/L · Symptoms: Confusion, lethargy, respiratory distress · Signs: Tachypnoea, tachycardia, hypotension Diagnosis · Lactate: > 2 mmol/L (normal < 2) · Anion gap: High · pH: Low · HCO■■: Low Management · Treat underlying cause: Restore perfusion · Fluid resuscitation: Isotonic saline · Vasopressors: For hypotension · Bicarbonate: Controversial (if pH < 7.0) · Consider: Haemodialysis (for severe cases) 3. Renal Failure (Uraemic Acidosis) Pathophysiology · Impaired excretion: Reduced GFR · Acid retention: H■ accumulation · Reduced bicarbonate reclamation: Impaired reabsorption · Reduced ammoniagenesis: Impaired NH■■ excretion Causes · Acute kidney injury: Pre-renal, intrinsic, post-renal · Chronic kidney disease: Progressive decline in GFR · End-stage renal disease: Dialysis dependence Clinical Features · Insidious onset: Often asymptomatic initially · Symptoms: Fatigue, nausea, vomiting, anorexia · Signs: Hypertension, oedema, uremic encephalopathy Diagnosis · Urea: Elevated · Creatinine: Elevated · GFR: Reduced · Anion gap: High (with phosphate, sulphate accumulation) · HCO■■: Low Management · Treat underlying condition: Correct reversible causes · Bicarbonate: If pH < 7.2, HCO■■ < 15 mEq/L · Dialysis: For severe metabolic acidosis with refractory uremia · Dietary modification: Protein restriction 4. Diarrhoea Pathophysiology · GI loss: Bicarbonate loss · HCO■■ loss: From intestinal secretions · Volume depletion: Reduced renal perfusion · Compensation: Renal response (may be impaired) Causes · Infectious diarrhoea: Bacterial, viral, parasitic · Chronic diarrhoea: IBD, malabsorption, irritable bowel syndrome · Laxative abuse: Secretory diarrhoea · Pancreatic insufficiency: Steatorrhoea Clinical Features · Acidosis: Variable severity · Symptoms: Diarrhoea, dehydration · Signs: Volume depletion, electrolyte disturbances Diagnosis · Anion gap: Normal (loss of bicarbonate) · HCO■■: Low · Urine Na■: Low (with volume depletion) · Urine pH: High (> 5.5, due to reduced H■ excretion) Management · Fluid replacement: Oral rehydration, IV fluids · Treat underlying cause: Antibiotics (if infectious) · Electrolyte replacement: Potassium, sodium · Bicarbonate: If severe acidosis 5. Renal Tubular Acidosis (Type 1, 2, or 4) Pathophysiology · Type 1 (Distal RTA): Impaired distal H■ secretion · Type 2 (Proximal RTA): Impaired proximal HCO■■ reabsorption · Type 4 (Hyperkalaemic RTA): Aldosterone deficiency or resistance Causes · Type 1: Autoimmune (Sjogren's), drugs (amphotericin B), obstructive uropathy · Type 2: Fanconi syndrome, drugs (acetazolamide), myeloma · Type 4: Diabetes mellitus, drugs (ACE inhibitors, spironolactone), aldosterone deficiency Clinical Features · Type 1: Nephrolithiasis, osteomalacia, hearing loss · Type 2: Growth retardation, hypophosphataemia, osteomalacia · Type 4: Hyperkalaemia, hypertension, salt wasting Diagnosis · Type 1: Urine pH > 5.5, low urine NH■■, positive anion gap, low urine K■ · Type 2: Urine pH > 5.5, positive bicarbonate loading, low phosphate · Type 4: Hyperkalaemia, low urine K■, high urine Na■, high urine pH Management · Type 1: Bicarbonate replacement (oral), potassium citrate · Type 2: Bicarbonate replacement, potassium, vitamin D · Type 4: Bicarbonate, potassium, mineralocorticoids if deficient Summary of Causes of Metabolic Acidosis Cause Pathophysiology Anion Gap Clinical Features DKA Ketone body accumulation High (≥ 12) Hyperglycaemia, ketonuria, dehydration, Kussmaul breathing Lactic acidosis Lactic acid accumulation High Tissue hypoxia, shock, severe illness Renal failure Acid retention, reduced H■ excretion High (with phosphate, sulphate) Elevated urea, creatinine, oliguria Diarrhoea Bicarbonate loss Normal Diarrhoea, dehydration, hypokalaemia RTA Impaired H■ secretion or HCO■■ reabsorption Normal (usually) Hypokalaemia, nephrolithiasis, growth retardation 5. METABOLIC ALKALOSIS Definition Metabolic alkalosis is a primary acid-base disorder characterized by a primary increase in plasma bicarbonate (> 28 mEq/L) and arterial pH (> 7.45), resulting from either: 1. Loss of acid (from GI or renal) 2. Gain of base (bicarbonate or alkali) 3. Extracellular fluid contraction Pathophysiology A. Generation Phase Acid Loss · GI loss: Vomiting, nasogastric suctioning · Renal loss: Loop diuretics, hyperaldosteronism Base Gain · Alkali ingestion: Bicarbonate, citrate · Alkali infusion: Bicarbonate therapy Extracellular Contraction · Volume depletion: Contraction alkalosis B. Maintenance Phase Volume Contraction · Renal response: Increased Na■/H■ exchange · HCO■■ reclamation: Increased proximal tubule reabsorption · Hypochloraemia: Reduced Cl■ availability for excretion Potassium Depletion · Intracellular shift: H■ enters cells, K■ leaves · Increased H■ secretion: To maintain electroneutrality · Paradoxical aciduria: Acidic urine despite alkalosis Aldosterone Excess · Increased Na■ reabsorption: Volume expansion · Increased H■ secretion: Distal tubule · Hypokalaemia: K■ loss Causes of Metabolic Alkalosis A. Chloride-Responsive Metabolic Alkalosis (Urine Cl■ < 20 mEq/L) GI Causes · Vomiting: Loss of gastric HCl · Nasogastric suctioning: Loss of gastric fluid · Pyloric stenosis: Gastric outlet obstruction Renal Causes · Diuretics: Loop and thiazide diuretics · Post-hypercapnia: Correction of respiratory acidosis · Chloride-wasting diarrhoea: Congenital chloride diarrhoea Other Causes · Volume contraction: Extracellular fluid depletion · Post-obstructive diuresis: Recovery from obstruction B. Chloride-Resistant Metabolic Alkalosis (Urine Cl■ > 20 mEq/L) Mineralocorticoid Excess · Primary hyperaldosteronism: Conn's syndrome · Secondary hyperaldosteronism: Renovascular hypertension, cirrhosis · Cushing's syndrome: Cortisol excess · Liddle's syndrome: Increased Na■ reabsorption Other Causes · Bartter's syndrome: Loop of Henle defect · Gitelman's syndrome: Distal tubule defect · Licorice ingestion: Inhibits 11β-HSD2, causes pseudohyperaldosteronism · Severe hypokalaemia: K■ depletion Compensatory Mechanisms A. Respiratory Compensation · Hypoventilation: Increased pCO■ · Mechanism: To retain CO■, offset alkalosis · Expected compensation: pCO■ increases 0.7 mmHg per 1 mEq/L increase in HCO■■ · Pulmonary response: Reduced ventilation rate B. Renal Compensation · Reduced H■ secretion: Conserve H■ · Reduced HCO■■ reclamation: Excrete HCO■■ · Increased HCO■■ excretion: In the urine · Time frame: Days to weeks Clinical Features A. Symptoms System Symptoms Muscular Weakness, cramps, spasms Neurological Confusion, irritability, seizures Cardiovascular Palpitations, arrhythmias, hypotension Respiratory Hypoventilation Gastrointestinal Nausea, vomiting General Fatigue, malaise B. Signs System Signs Cardiovascular Hypotension, tachycardia, arrhythmias Respiratory Hypoventilation, tachypnoea Muscular Weakness, fasciculations, tetany Neurological Confusion, altered mental status Diagnosis A. Laboratory Findings Parameter Metabolic Alkalosis pH 7.45 HCO■■ 28 mEq/L pCO■ Increased (compensatory) Serum electrolytes Hypokalaemia, hypochloraemia Anion gap Normal (unless mixed disorder) Urine Cl■ < 20 (chloride-responsive) or > 20 (chloride-resistant) B. Investigations Urine Cl■ Measurement · < 20 mEq/L: Chloride-responsive · > 20 mEq/L: Chloride-resistant Urine K■ · Low: K■ depletion · High: Aldosterone excess Aldosterone/Renin Ratio · High: Hyperaldosteronism · Low: Other causes Management A. Chloride-Responsive Metabolic Alkalosis Principles 1. Treat underlying cause: Stop vomiting, remove NG tube 2. Administer NaCl: 0.9% saline to correct volume depletion 3. Correct hypokalaemia: KCl (oral or IV) 4. Monitor: Electrolytes, acid-base status Specific Management · Vomiting: Antiemetics, acid suppression · Diuretics: Stop or adjust dose · Hypokalaemia: Oral or IV potassium supplementation B. Chloride-Resistant Metabolic Alkalosis Principles 1. Treat underlying cause: Remove aldosterone-secreting tumour 2. Correct potassium: KCl to replace total body K■ deficit 3. Specific therapy: Mineralocorticoid receptor antagonists (spironolactone, eplerenone) 4. Monitor: Blood pressure, electrolytes, acid-base status Specific Management · Primary hyperaldosteronism: Surgery (adenoma), spironolactone (bilateral) · Cushing's syndrome: Treat underlying condition · Bartter's syndrome: Spironolactone, potassium supplementation Complications Complication Mechanism Cardiac arrhythmias Hypokalaemia, hypocalcaemia Muscle weakness Hypokalaemia Tetany Hypocalcaemia (due to alkalosis-induced calcium binding) Seizures Electrolyte disturbances Dysrhythmias Risk of ventricular arrhythmias 6. MAINTENANCE OF ACID-BASE HOMEOSTASIS THROUGH BUFFER REGENERATION Introduction Buffer regeneration is a crucial mechanism for maintaining acid-base homeostasis. Buffers can be regenerated through metabolic processes, ensuring that the body's buffering capacity is continuously restored. Buffer Systems A. Intracellular Buffers Components · Proteins: Most abundant (albumin, haemoglobin) · Phosphate: Important in intracellular and urinary buffering · Organic phosphates: ATP, ADP, creatine phosphate · Cellular proteins: Act as buffers Mechanisms · Proteins: Imidazole group of histidine (pKa ~7.4) · Phosphate: HPO■²■/H■PO■■ (pKa ~6.8) · Haemoglobin: Imidazole group (pKa 7.2-7.4) B. Extracellular Buffers Components · Bicarbonate: Most important extracellular buffer · Proteins: Especially albumin · Phosphate: Small role Mechanisms · Bicarbonate: HCO■■ + H■ → H■CO■ → CO■ + H■O (carbonic anhydrase) · Proteins: Histidine residues · Phosphate: HPO■²■ + H■ → H■PO■■ C. Urinary Buffer Components · Phosphate: HPO■²■/H■PO■■ · Ammonia: NH■/NH■■ · Creatinine: Small role Buffer Regeneration Mechanisms A. Bicarbonate Regeneration Renal Regeneration · Ammoniagenesis: Glutamine → NH■■ + HCO■■ · Titratable acid excretion: Phosphate buffering · Net acid excretion: H■ excretion equals bicarbonate generation Hepatic Regeneration · Urea cycle: NH■ → urea (consumes H■) · Glutamine metabolism: NH■ → glutamine · Lactate metabolism: Lactate → glucose Gastrointestinal Regeneration · Bicarbonate secretion: GI tract secretes HCO■■ · Alkaline tide: Post-prandial HCO■■ generation B. Phosphate Regeneration Bone Resorption · Buffering: Bone releases phosphate and bicarbonate · Process: H■ neutralization by bone minerals Urinary Excretion · Phosphate buffering: Titratable acid excretion · Regeneration: Renal reabsorption C. Protein Buffer Regeneration Metabolism · Amino acids: Converted to intermediates that generate HCO■■ · Glutamine: Major source of HCO■■ · Urea cycle: Generates HCO■■ Maintenance of Buffer Systems A. Renal Mechanisms Ammoniagenesis · Glutamine metabolism: Glutamine → NH■■ + HCO■■ · Regulation: Stimulated by acidosis · Effect: Generates new HCO■■ Titratable Acid Excretion · Phosphate: HPO■²■ + H■ → H■PO■■ · Sulphate: SO■²■ + H■ → HSO■■ · Organic acids: Excretion in urine Net Acid Excretion · Definition: NH■■ + titratable acid - HCO■■ · Normal: 40-80 mEq/day · Acidosis: Increased excretion B. Respiratory Mechanisms CO■ Excretion · Mechanism: CO■ + H■O ↔ H■CO■ ↔ H■ + HCO■■ · Regulation: Ventilation rate and depth · Effect: pH is regulated by altering CO■ excretion Bicarbonate Regeneration · RBC: Carbonic anhydrase converts CO■ to HCO■■ · Tissue: HCO■■ moves into blood C. Hepatic Mechanisms Urea Cycle · NH■ + CO■ + H■O: → Urea + 2 H■ + HCO■■ · Effect: Consumes H■, generates HCO■■ · Acidosis: Enhances urea synthesis Gluconeogenesis · Lactate: Converted to glucose (consumes H■) · Amino acids: Contribute to gluconeogenesis · Effect: Generates HCO■■ Regulation of Buffer Regeneration A. Endocrine Regulation Hormone Effect on H■ Balance Mechanism Aldosterone Increases H■ secretion Distal tubule H■-ATPase Angiotensin II Increases H■ secretion Na■/H■ exchange PTH Decreases H■ secretion Inhibits proximal HCO■■ reabsorption ADH Increases water retention Affects acid-base balance Cortisol Increases H■ secretion Mineralocorticoid effect Insulin Increases H■ secretion Stimulates Na■/H■ exchange B. Metabolic Regulation Factor Effect Mechanism Acidosis Increased regeneration Stimulates ammoniagenesis Alkalosis Decreased regeneration Inhibits ammoniagenesis K■ status Affects H■ secretion H■/K■ exchange Na■ status Affects H■ secretion Na■/H■ exchange Volume status Affects H■ secretion Distal tubule Clinical Significance A. Acid-Base Disorders Metabolic Acidosis · Buffering: Bicarbonate consumed · Regeneration: Increased renal ammoniagenesis, increased titratable acid · Response: Compensatory hyperventilation Metabolic Alkalosis · Buffering: Bicarbonate generated · Regeneration: Decreased renal regeneration · Response: Compensatory hypoventilation Respiratory Acidosis · Buffering: Bicarbonate generated by RBC · Regeneration: Increased renal H■ secretion · Response: Renal compensation Respiratory Alkalosis · Buffering: Bicarbonate consumed · Regeneration: Reduced renal H■ secretion · Response: Renal compensation B. Clinical Assessment Bicarbonate Measurement · Total CO■: Measures CO■, HCO■■, H■CO■ · HCO■■: Direct measurement of bicarbonate · pH: Indirect measure of acid-base status Anion Gap · Calculation: Na■ - (Cl■ + HCO■■) · Normal: 10-20 mEq/L · Increased: Metabolic acidosis (unmeasured anions) · Decreased: Metabolic alkalosis (unmeasured cations) 7. ANION GAP CALCULATION AND SIGNIFICANCE IN DIABETIC PATIENT Patient Data Parameter Value Reference Range Sodium (Na■) 136 mmol/L 135-145 mmol/L Potassium (K■) 5 mmol/L 3.5-5.0 mmol/L Chloride (Cl■) 97 mmol/L 95-105 mmol/L Bicarbonate (HCO■■) 13 mmol/L 22-28 mmol/L Calculation of Anion Gap A. Basic Anion Gap Calculation Formula Anion Gap (AG) = Na■ - (Cl■ + HCO■■) Calculation AG = 136 - (97 + 13) AG = 136 - 110 AG = 26 mmol/L B. Interpretation of Anion Gap Normal Anion Gap: 10-20 mmol/L (average 12 mmol/L) Interpretation · AG = 26 mmol/L: Increased anion gap metabolic acidosis · Unmeasured anions: Present (ketones, lactate, etc.) · Acidosis: Significant metabolic acidosis Significance in a Diabetic Patient A. Clinical Context Diabetic Patient · Diabetes mellitus: Type 1 or type 2 · Presentation: Likely with symptoms of diabetic ketoacidosis (DKA) · History: Polyuria, polydipsia, weight loss · Symptoms: Nausea, vomiting, abdominal pain, lethargy B. Differential Diagnosis Increased Anion Gap Metabolic Acidosis 1. Diabetic ketoacidosis (DKA) – Most likely in a diabetic patient 2. Lactic acidosis – Possible if hypotensive, septic, or hypoxic 3. Renal failure – Uraemic acidosis if renal impairment 4. Salicylate toxicity – If ingested 5. Methanol or ethylene glycol poisoning – Usually not in typical diabetic C. Interpretation in DKA Pathophysiology · Insulin deficiency: Leading to hyperglycaemia · Lipolysis: Free fatty acid release · Ketogenesis: Acetoacetate, β-hydroxybutyrate production · Acidosis: Ketone body accumulation Electrolyte Changes · Potassium: May be normal or high (despite total body deficit) · Sodium: May be low (due to hyperglycaemia-related shifts) · Chloride: Usually normal or low Anion Gap and Acidosis · Increased gap: 26 mmol/L (due to ketone bodies) · Bicarbonate: Low (13 mmol/L) · pH: Likely low (< 7.35) D. Clinical Significance Severity Assessment Anion Gap Severity 10-20 Normal 20-30 Moderate acidosis > 30 Severe acidosis AG = 26 mmol/L: Moderate acidosis Clinical Implications · Diagnosis: Supports diagnosis of DKA · Severity: Moderate acidosis, requires urgent management · Management: 1. Fluid resuscitation: Isotonic saline 2. Insulin: IV infusion 3. Potassium: Replacement 4. Monitor: Glucose, electrolytes, acid-base status 5. Reassess: Anion gap to monitor response E. Corrected Sodium Calculation For Hyperglycaemia · Correction factor: Na■ increases 1.6 mmol/L for every 100 mg/dL (5.6 mmol/L) increase in glucose above 100 mg/dL If glucose is elevated (as likely in DKA) · Corrected Na■ = Measured Na■ + 0.016 × (Glucose - 100) · Interpretation: Helps assess true sodium status 8. ANION GAP Definition Anion gap is the difference between the measured cations (sodium) and measured anions (chloride and bicarbonate) in plasma. It represents the concentration of unmeasured anions (phosphate, sulphate, proteins, organic acids). Calculation Formula Anion Gap (AG) = Na■ - (Cl■ + HCO■■) Alternative Formula AG = (Na■ + K■) - (Cl■ + HCO■■) Normal Value · Without potassium: 10-20 mmol/L (average 12 mmol/L) · With potassium: 12-24 mmol/L (ave
Kidney
Standard Answer:
1. INVESTIGATION OF PROTEINURIA Definition Proteinuria is the presence of excess protein in the urine. It can be a sign of renal disease, but can also be benign or physiological. Classification of Proteinuria A. By Quantity Type Protein Excretion Microalbuminuria 30-300 mg/24 hours Clinical proteinuria 300 mg/24 hours Nephrotic range proteinuria 3.5 g/24 hours B. By Mechanism Type Mechanism Examples Glomerular Increased glomerular permeability Glomerulonephritis, diabetic nephropathy Tubular Impaired tubular reabsorption Tubulointerstitial disease, Fanconi syndrome Overflow Excess production of low molecular weight proteins Multiple myeloma, myeloma Functional Physiological response Fever, exercise, stress Orthostatic Postural changes Benign, positional Bence Jones Monoclonal light chains Multiple myeloma Investigations for Proteinuria A. Initial Investigations 1. Urine Dipstick · Principle: Colorimetric reaction (pH change) · Sensitivity: Detects > 300 mg/L (albumin) · Limitations: · Not quantitative · Only detects albumin (not globulins) · False positives (alkaline urine, concentrated urine) · False negatives (dilute urine, non-albumin proteins) · Interpretation: Positive test requires further evaluation 2. Urine Protein-to-Creatinine Ratio (UPCR) · Principle: Measures protein and creatinine in spot urine · Formula: Urine protein (mg/dL) / Urine creatinine (mg/dL) · Interpretation: · < 0.2: Normal · 0.2-3.0: Proteinuria · 3.0: Nephrotic range · Advantages: · Convenient · Correlates with 24-hour collection · More accurate than dipstick · Limitations: · Not diagnostic of cause · Variability 3. Urine Albumin-to-Creatinine Ratio (UACR) · Principle: Measures albumin and creatinine in spot urine · Formula: Urine albumin (mg/L) / Urine creatinine (g/L) · Interpretation: · < 30 mg/g: Normal · 30-300 mg/g: Microalbuminuria · 300 mg/g: Clinical proteinuria · Advantages: · Sensitive for early diabetic nephropathy · Gold standard · Limitations: · Variability · Requires specific assay 4. 24-Hour Urine Collection · Principle: Quantitative measurement over 24 hours · Interpretation: · < 150 mg/24h: Normal · 150-300 mg/24h: Microalbuminuria · 300 mg/24h: Clinical proteinuria · Advantages: · Gold standard for quantification · Disadvantages: · Inconvenient · Prone to collection errors B. Further Investigations 1. Urine Protein Electrophoresis · Principle: Separates proteins by charge/molecular weight · Uses: Identifies type of proteinuria · Patterns: · Glomerular: Albumin predominant · Tubular: Mixed low molecular weight proteins · Overflow: Monoclonal band (Bence Jones) · Clinical Significance: Differentiates between glomerular and tubular causes 2. Immunofixation · Principle: Identifies immunoglobulin classes · Uses: Confirm monoclonal bands · Specificity: Highly specific for monoclonal gammopathy 3. Serum Protein Electrophoresis · Principle: Separates serum proteins · Uses: Identify monoclonal gammopathy · Correlation: With urinary findings 4. Renal Biopsy · Indication: Diagnostic confirmation · Uses: · Histological classification · Guide treatment · Prognosis 5. Other Investigations Investigation Purpose Serum creatinine, urea, eGFR Assess renal function Serum electrolytes Assess metabolic status Serum albumin Assess protein loss Serum lipids Assess nephrotic syndrome ANA, anti-dsDNA, complement Autoimmune work-up Hepatitis B/C, HIV serology Infective causes Immunoglobulins (serum and urine) Monoclonal gammopathy Approach to Proteinuria Investigation Algorithm Step 1: Confirm Proteinuria · Dipstick: Positive → Confirm with UPCR or 24-hour collection · False positive: Check for causes (alkaline urine, infection) Step 2: Quantify Proteinuria · UPCR or 24-hour collection: Assess severity · Interpretation: < 0.2 (normal), 0.2-3.0 (proteinuria), > 3.0 (nephrotic) Step 3: Determine Type of Proteinuria Finding Interpretation Cause Albuminuria predominant Glomerular Glomerulonephritis, diabetic nephropathy Mixed low molecular weight Tubular Tubulointerstitial disease Monoclonal band Overflow Multiple myeloma Normal findings Functional Fever, exercise, stress Step 4: Assess Renal Function · eGFR, creatinine, urea: Assess severity of renal impairment · Electrolytes: Assess metabolic complications Step 5: Investigate Underlying Cause · Clinical correlation: History, examination · Specific tests: Based on suspected cause Clinical Scenarios and Investigation Strategy Clinical Scenario Investigations Suspected glomerular disease UACR, UPCR, ANA, complement, hepatitis B/C, HIV, renal biopsy Suspected tubular disease UPCR, urine amino acids, electrolytes, renal ultrasound Suspected overflow proteinuria Serum protein electrophoresis, immunofixation, urine electrophoresis Suspected diabetic nephropathy UACR (microalbuminuria), HbA1c, renal function Suspected pre-eclampsia UACR, blood pressure, uric acid, renal function Transient/functional proteinuria Repeat testing, investigations to rule out pathology Clinical Significance Proteinuria Level Clinical Significance Microalbuminuria Early marker of diabetic nephropathy, cardiovascular risk Clinical proteinuria (300-3500 mg/24h) Significant renal disease Nephrotic range (> 3.5 g/24h) Nephrotic syndrome, significant protein loss Monoclonal band Multiple myeloma, monoclonal gammopathy Mixed low molecular weight Tubular damage, heavy metal toxicity, drug toxicity 2. POLYURIA Definition Polyuria is defined as excessive urine production, typically > 3 L/day (in adults) or > 40 mL/kg/day. It results from either increased water intake (primary polydipsia) or impaired renal water conservation (diabetes insipidus). Pathophysiology A. Normal Water Homeostasis Osmoregulation · Hypothalamus: Osmoreceptors detect changes in plasma osmolality · ADH release: Increases with increased osmolality · Kidney: ADH stimulates water reabsorption in collecting ducts · Thirst: Stimulates water intake when osmolality > 290 mOsm/kg Regulation of ADH · Plasma osmolality: Main regulator · Volume status: Volume depletion stimulates ADH · Stress: Pain, nausea, hypoglycaemia stimulate ADH · Drugs: Nicotine, morphine stimulate ADH; alcohol, lithium inhibit ADH B. Mechanisms of Polyuria 1. Osmotic Diuresis · Causes: Glucose (diabetes mellitus), mannitol, urea · Mechanism: Unabsorbed solute in tubule → osmotic gradient → increased urine flow · Features: Polyuria with normal or high urine osmolality (due to solute load) 2. Water Diuresis · Causes: Diabetes insipidus (central or nephrogenic), primary polydipsia · Mechanism: Reduced ADH effect → decreased water reabsorption → dilute urine · Features: Polyuria with low urine osmolality (< 300 mOsm/kg) 3. Impaired Concentration · Causes: Chronic kidney disease, interstitial nephritis · Mechanism: Reduced concentrating ability · Features: Polyuria with impaired osmolality Causes of Polyuria A. Osmotic Diuresis Cause Pathophysiology Diabetes mellitus Glucosuria, osmotic diuresis Mannitol infusion Osmotic load High protein intake Urea load Diuretics Loop diuretics, osmotic diuretics Chronic kidney disease Urea retention, osmotic effect B. Water Diuresis Central Diabetes Insipidus (CDI) · Cause: Deficient ADH production · Causes: · Idiopathic · Trauma · Tumours (craniopharyngioma, metastasis) · Infection · Genetic (autosomal dominant) · Features: Rapid onset, polyuria, polydipsia Nephrogenic Diabetes Insipidus (NDI) · Cause: Impaired renal response to ADH · Causes: · Genetic (X-linked, autosomal recessive) · Drug-induced (lithium, demeclocycline) · Chronic renal disease · Hypercalcaemia, hypokalaemia · Features: Polyuria, polydipsia Primary Polydipsia (Psychogenic Polydipsia) · Cause: Excessive water intake · Mechanism: Suppresses ADH → dilute urine · Features: Polyuria, polydipsia, normal osmolality C. Impaired Concentration Cause Pathophysiology Chronic kidney disease Reduced concentrating ability Interstitial nephritis Damage to medullary interstitium Amyloidosis Deposition in kidney Sickle cell disease Medullary vascular damage Urinary tract obstruction Impaired concentrating ability Investigation of Polyuria A. Initial Investigations 1. Serum Osmolality · Normal: 280-295 mOsm/kg · Interpretation: · High (> 300): Osmotic diuresis (e.g., diabetes mellitus) or impaired concentration · Normal: Primary polydipsia · Low (< 275): Water diuresis (e.g., diabetes insipidus) 2. Urine Osmolality · Normal: 300-900 mOsm/kg · Interpretation: · Low (< 300): Diabetes insipidus, primary polydipsia · High (> 600): Osmotic diuresis 3. Serum and Urine Sodium · Serum sodium: Hypernatraemia (water diuresis), hyponatremia (primary polydipsia) · Urine sodium: Assess volume status 4. Fasting Plasma Glucose · Purpose: Rule out diabetes mellitus · Interpretation: > 7.0 mmol/L (diagnostic) 5. Serum Potassium and Calcium · Purpose: Identify electrolyte causes · Hypercalcaemia: Causes nephrogenic DI · Hypokalaemia: Causes nephrogenic DI 6. Renal Function · Urea, creatinine, eGFR: Assess renal function · Interpretation: Impaired concentration if renal failure B. Water Deprivation Test Indication: Differentiate between types of diabetes insipidus Procedure 1. Baseline: Measure plasma osmolality, urine osmolality, weight 2. Withhold fluids: For 4-8 hours (monitor weight) 3. Hourly: Measure urine osmolality, urine volume 4. Stop: Weight loss > 3% or progressive hypernatraemia Interpretation Condition Response to Water Deprivation Response to DDAVP (ADH) Normal Urine osmolality > 800 mOsm/kg Minimal change Central DI No increase (< 300 mOsm/kg) Increase to > 300 mOsm/kg Nephrogenic DI No increase (< 300 mOsm/kg) No increase (< 300 mOsm/kg) Primary polydipsia Urine osmolality > 500 mOsm/kg (mild) Minimal change Protocol · Duration: 8 hours (adults), 4-6 hours (children) · Weight monitoring: Every hour · Stop criteria: Weight loss > 3%, hypernatraemia, severe thirst C. DDAVP (Desmopressin) Test Indication: Differentiate central from nephrogenic DI Procedure 1. Baseline: Plasma osmolality, urine osmolality 2. DDAVP administration: 2 µg IM or intranasal 3. After 2 hours: Measure urine osmolality 4. Interpretation: Rise in urine osmolality > 50% = central DI D. Imaging Studies MRI Brain · Purpose: Identify hypothalamic-pituitary lesions · Findings: Pituitary stalk thickening, absence of posterior pituitary bright spot · Indications: Suspected central DI, anatomical lesions Renal Ultrasound · Purpose: Identify structural abnormalities · Indications: Suspected nephrogenic DI, chronic kidney disease Clinical Approach to Polyuria Clinical Presentation Investigation Interpretation Polyuria, polydipsia, normal glucose Water deprivation test, urine osmolality Differentiate DI from polydipsia Polyuria, polydipsia, high glucose Fasting blood glucose, HbA1c Diabetes mellitus Polyuria, polydipsia, normal osmolality Water deprivation test Primary polydipsia Polyuria, polydipsia, high osmolality Water deprivation test Diabetes insipidus Polyuria, polydipsia, low osmolality Water deprivation test Primary polydipsia, psychogenic 3. TESTS OF GLOMERULAR FUNCTION Introduction Glomerular function is assessed by measuring the ability of the glomerulus to filter blood and produce urine. The main tests evaluate: 1. Glomerular filtration rate (GFR) – the rate at which blood is filtered 2. Glomerular permeability – the ability to retain proteins and cells Tests of Glomerular Filtration A. Serum Creatinine Measurement · Source: Creatinine is a waste product of muscle metabolism · Production: Relatively constant, proportional to muscle mass · Excretion: Nearly entirely by glomerular filtration Interpretation · Normal: 60-120 µmol/L · Elevated: Indicates decreased GFR · Limitations: · Affected by muscle mass (age, sex, ethnicity) · Affected by diet · Not sensitive for early reduction in GFR Clinical Significance · Creatinine elevation (acute/chronic): Suggests renal impairment · Creatinine clearance: More accurate assessment B. Estimated GFR (eGFR) Formula · MDRD (Modification of Diet in Renal Disease) equation · Cockcroft-Gault equation · CKD-EPI equation (more accurate) Interpretation · Normal: > 90 mL/min/1.73m² · Stage 1: > 90 (normal, with other evidence of kidney damage) · Stage 2: 60-89 (mildly reduced) · Stage 3: 30-59 (moderately reduced) · Stage 4: 15-29 (severely reduced) · Stage 5: < 15 (kidney failure) Limitations · Not valid: In acute kidney injury, extremes of age, muscle wasting, pregnancy C. Creatinine Clearance Measurement · Collection: 24-hour urine collection · Formula: Urine creatinine × Urine volume / Plasma creatinine · Correction: To body surface area (1.73 m²) Interpretation · Normal: 90-120 mL/min/1.73m² · Reduced: Indicates renal impairment · Advantages: More accurate than serum creatinine alone · Limitations: Requires 24-hour collection, prone to collection errors D. Inulin Clearance (Gold Standard) Measurement · Infusion: Inulin is infused intravenously · Collection: Timed urine collection · Calculation: Clearance = Urine concentration × Flow rate / Plasma concentration Advantages · Gold standard: Most accurate measurement of GFR · Not affected: By metabolism or protein binding Disadvantages · Invasive: Requires infusion and multiple blood samples · Time-consuming: Not practical for routine use E. Cystatin C Measurement · Source: Produced by all nucleated cells · Production: Constant, not affected by muscle mass · Excretion: Filtered by glomerulus, not reabsorbed Interpretation · Elevated: Indicates decreased GFR · Advantages: More sensitive than creatinine, not affected by muscle mass · Limitations: More expensive, less widely available Tests of Glomerular Permeability A. Proteinuria (as discussed) Measurement · Dipstick: Screening · Quantitative: 24-hour collection, protein-to-creatinine ratio Interpretation · Microalbuminuria: 30-300 mg/24h (early glomerular damage) · Clinical proteinuria: > 300 mg/24h (established glomerular disease) · Nephrotic range: > 3.5 g/24h (nephrotic syndrome) Clinical Significance · Glomerular damage: Increased permeability · Diabetic nephropathy: Microalbuminuria = early detection · Glomerulonephritis: Variable proteinuria · Nephrotic syndrome: Heavy proteinuria B. Urine Sediment Analysis Erythrocytes · Hematuria: > 3 RBCs per high power field · Dysmorphic RBCs: Indicates glomerular origin · RBC casts: Indicates glomerular bleeding Leucocytes · Pyuria: > 10 WBCs per high power field · White cell casts: Indicates inflammation Casts · RBC casts: Glomerular bleeding (e.g., IgA nephropathy) · WBC casts: Tubulointerstitial disease · Granular casts: Nonspecific, indicates renal disease Crystals · Urinary crystals: Can indicate metabolic disorders Tests of Glomerular Function Summary Test What it measures Interpretation Clinical Use Serum creatinine GFR (indirect) Elevated = decreased GFR Screening, monitoring eGFR GFR (calculated) Reduced = renal impairment Screening, staging CKD Creatinine clearance GFR (direct) Reduced = renal impairment More accurate assessment Cystatin C GFR (indirect) Elevated = decreased GFR More sensitive in elderly Inulin clearance GFR (gold standard) Reduced = renal impairment Research, special cases Proteinuria Permeability Increased = glomerular damage Detect glomerular disease Microalbuminuria Early glomerular damage Positive = early nephropathy Diabetes screening Clinical Approach to Glomerular Function Testing Step 1: Suspect Renal Disease · Symptoms: Oedema, hypertension, oliguria, haematuria · Signs: Proteinuria, haematuria, hypertension Step 2: Initial Assessment · Blood tests: Creatinine, urea, electrolytes, eGFR · Urine tests: Dipstick, protein-to-creatinine ratio, sediment Step 3: Further Assessment · If abnormal: More specific tests (creatinine clearance, 24-hour urine) · If indicated: Renal biopsy, imaging Step 4: Monitoring · Serial measurements: Assess progression or response to treatment · Monitor: Creatinine, eGFR, proteinuria 4. TESTS OF RENAL TUBULAR FUNCTION Introduction Renal tubular function tests assess the ability of the renal tubules to: 1. Reabsorb substances (electrolytes, glucose, amino acids, water) 2. Secrete substances (H■, organic acids, drugs) 3. Concentrate or dilute urine 4. Excrete waste products Tests of Proximal Tubular Function A. Urinary pH and Bicarbonate Handling Fractional Excretion of Bicarbonate (FEHCO■) · Measurement: (Urine HCO■■ × Plasma Creatinine) / (Plasma HCO■■ × Urine Creatinine) × 100 · Normal: < 1% (in acidemia), < 5% (in acidosis) · Interpretation: · 5% in acidosis: Impaired proximal HCO■■ reabsorption (Type 2 RTA) · Significance: Distinguishes proximal from distal RTA B. Aminoaciduria Urine Amino Acid Screen · Measurement: Qualitative or quantitative amino acids · Normal: Minimal amino acids in urine · Abnormal: Generalized aminoaciduria (Fanconi syndrome) · Specific: Cystinuria (specific amino acid transport defect) C. Glycosuria Renal Glycosuria · Cause: Impaired glucose reabsorption in proximal tubule · Diagnosis: Glucosuria in the presence of normal blood glucose · Significance: Benign condition, but indicates tubular dysfunction D. Low Molecular Weight Proteinuria Urine Protein Electrophoresis · Pattern: Mixed low molecular weight proteins (β■-microglobulin, α■-microglobulin) · Interpretation: Indicates tubular dysfunction · Examples: Fanconi syndrome, tubulointerstitial nephritis E. Fanconi Syndrome Tests Findings · Glycosuria: Normal glucose · Aminoaciduria: Generalized · Phosphaturia: Low phosphate · Bicarbonaturia: Metabolic acidosis · Proteinuria: Low molecular weight proteins Tests of Distal Tubular Function A. Urine Acidification Test NH■Cl Loading Test · Procedure: Administer NH■Cl (0.1 g/kg) orally · Effect: Acid load → distal tubule should acidify urine · Normal: Urine pH falls below 5.5 · Interpretation: Failure indicates Type 1 RTA B. Urine pH and Anion Gap Urine pH · Normal: 4.5-8.0 (varies with acid-base status) · In acidosis: < 5.5 (normal response) · In Type 1 RTA: > 5.5 (inability to acidify) Urine Anion Gap · Formula: Na■ + K■ - Cl■ (urine) · Normal: 0-10 mEq/L (positive) · In Type 1 RTA: Positive (inability to excrete NH■■) · In Type 2 RTA: Negative (ability to excrete NH■■) C. Concentration and Dilution Tests Water Deprivation Test · Procedure: Withhold fluids for 8-12 hours · Normal: Urine osmolality > 800 mOsm/kg · Abnormal: Inability to concentrate (diabetes insipidus, chronic kidney disease) Furosemide Test · Procedure: Furosemide (1 mg/kg IV) → stimulates ADH-independent concentration · Normal: Urine osmolality > 500 mOsm/kg · Abnormal: Inability to concentrate (damage to ascending limb) D. Potassium Handling Urine Potassium Excretion · Measurement: 24-hour urine potassium · Normal: Varies with intake · Interpretation: Assess potassium-wasting Transtubular Potassium Gradient (TTKG) · Formula: [Urine K■ × Plasma Osmolality] / [Plasma K■ × Urine Osmolality] · Normal: 5-12 · Interpretation: > 7 indicates K■ wasting, < 3 indicates impaired K■ excretion Tests of Loop of Henle Function A. Urinary Calcium and Magnesium Calcium Excretion · Normal: < 0.02 (Ca/Cr ratio) · Hypercalciuria: Increased calcium excretion · Significance: Associated with nephrolithiasis, tubular dysfunction Magnesium Excretion · Normal: 0.05-0.10 mmol/mmol creatinine · Hypomagnesaemia: Indicates tubular Mg²■ wasting B. Osmolality and Electrolyte Excretion Urine Osmolality · Normal: 300-900 mOsm/kg (depends on hydration) · Inability to concentrate: Tubular dysfunction Fractional Excretion of Sodium (FENa) · Formula: (Urine Na■ × Plasma Creatinine) / (Plasma Na■ × Urine Creatinine) × 100 · Normal: < 1% · Interpretation: · < 1%: Pre-renal cause (e.g., volume depletion) · 2%: Intrinsic renal cause (e.g., ATN) Fractional Excretion of Urea (FEUrea) · Formula: (Urine Urea × Plasma Creatinine) / (Plasma Urea × Urine Creatinine) × 100 · Interpretation: · < 35%: Pre-renal cause · 35%: Intrinsic renal cause Clinical Application of Tubular Function Tests Test Purpose Interpretation Clinical Use FEHCO■ Proximal HCO■■ reabsorption 5% in acidosis = Type 2 RTA Distinguish RTA types Urine amino acids Proximal amino acid transport Generalized = Fanconi syndrome Diagnosis of Fanconi Urine pH Distal acidification 5.5 in acidosis = Type 1 RTA Distinguish RTA types Water deprivation Concentration ability < 800 mOsm/kg = defect Diabetes insipidus FENa Sodium reabsorption 2% = intrinsic renal cause Acute kidney injury TTKG Potassium handling 7 = K■ wasting Hyperkalaemia work-up 5. CREATININE CLEARANCE TEST Definition Creatinine clearance is the volume of plasma that is cleared of creatinine per unit time. It is a measure of glomerular filtration rate (GFR), as creatinine is nearly completely filtered by the glomerulus and not reabsorbed. Indications · Assessment of renal function: More accurate than serum creatinine alone · Monitoring renal disease: Progressive loss of renal function · Drug dosing: Adjusting doses of renally excreted drugs · Assessment of prognosis: In chronic kidney disease · Evaluation of renal donors: Pre-transplant assessment Calculation of Creatinine Clearance A. 24-Hour Urine Collection Method Formula Creatinine Clearance (mL/min) = (Urine Creatinine (µmol/L) × Urine Volume (mL/24h)) / (Plasma Creatinine (µmol/L) × 1440 min/day) Steps 1. Collect urine: 24-hour urine collection 2. Measure: Total volume 3. Measure: Urine creatinine concentration 4. Measure: Plasma creatinine concentration 5. Calculate: Using the formula above Correction for Body Surface Area · Formula: Result × 1.73 / BSA (in m²) · BSA: Body surface area (Mosteller formula) Reference Range · Normal: 90-120 mL/min/1.73m² · Reduced: Indicates renal impairment B. Calculation Method Example · Urine creatinine: 800 µmol/L · Urine volume: 1800 mL/24h · Plasma creatinine: 100 µmol/L Calculation · Clearance = (800 × 1800) / (100 × 1440) = 10 mL/min · Correction for BSA: 1.73/1.73 = 1 → 10 mL/min Interpretation · Normal: 90-120 mL/min · Mild reduction: 60-89 mL/min · Moderate reduction: 30-59 mL/min · Severe reduction: 15-29 mL/min · Kidney failure: < 15 mL/min Alternative Methods for Estimating GFR A. Cockcroft-Gault Equation Formula · Male: [(140 - Age) × Weight (kg)] / (72 × Serum Creatinine (mg/dL)) · Female: 0.85 × [(140 - Age) × Weight (kg)] / (72 × Serum Creatinine (mg/dL)) Advantages · Simple: Clinical use · Accounts for: Age, sex, weight Limitations · Not corrected: For BSA · Not accurate: In extremes of weight, muscle mass B. MDRD Equation Formula · GFR (mL/min/1.73m²) = 175 × (Serum Creatinine)^-1.154 × (Age)^-0.203 × 0.742 (if female) × 1.212 (if African American) Advantages · Corrected: For BSA · More accurate: In moderate to severe renal impairment Limitations · Not validated: In acute kidney injury, extremes of age, muscle wasting, pregnancy C. CKD-EPI Equation Formula · GFR (mL/min/1.73m²) = 141 × min(Serum Creatinine/κ, 1)^α × max(Serum Creatinine/κ, 1)^-1.209 × 0.993^Age × 1.018 (if female) × 1.159 (if African American) · κ: 0.7 (females), 0.9 (males) · α: -0.329 (females), -0.411 (males) Advantages · More accurate: In mild renal impairment · Less affected: By muscle mass Limitations · Not validated: In acute kidney injury, extremes of age Clinical Interpretation A. Factors Affecting Creatinine Clearance Factor Effect Age Decreases with age (1 mL/min/year) Sex Lower in females (due to lower muscle mass) Muscle mass Lower in low muscle mass, higher in high muscle mass Diet High protein increases creatinine Medications Cimetidine, trimethoprim, etc. decrease secretion Exercise Increases creatinine production Disease Renal disease decreases clearance B. Interpretation Algorithm If Serum Creatinine is Elevated 1. Assess clinical status: Acute or chronic? 2. Estimate GFR: Using eGFR equations 3. Measure creatinine clearance: If precise measurement needed 4. Monitor: Serial measurements to assess progression If Creatinine Clearance is Reduced 1. Assess for renal disease: Check urine dipstick, sediment 2. Evaluate cause: Pre-renal, intrinsic, post-renal 3. Stage CKD: Using eGFR 4. Manage: According to CKD stage Clinical Applications Situation Creatinine Clearance Use Interpretation Screening eGFR Identify renal impairment Staging CKD eGFR (MDRD, CKD-EPI) Stage CKD (1-5) Drug dosing eGFR or creatinine clearance Adjust drug doses Pre-transplant Creatinine clearance, radionuclide scan Assess renal function Acute kidney injury eGFR (with care) Assess severity Limitations of Creatinine Clearance Limitation Description Collection errors Incomplete 24-hour collection (common) Day-to-day variability Variations in diet, hydration, exercise Affected by muscle mass Overestimates in low muscle mass, underestimates in high muscle mass Drug interference Some drugs inhibit secretion Tubular secretion Creatinine is secreted (minor), leading to overestimation Time-consuming Requires 24-hour collection 6. BIOCHEMICAL INVESTIGATION OF POLYURIA Introduction Polyuria is defined as excessive urine output (> 3 L/day in adults). The biochemical investigation aims to: 1. Confirm polyuria 2. Differentiate causes (osmotic vs. water diuresis) 3. Identify underlying condition Initial Investigations A. History and Examination History · Onset: Acute or chronic · Fluid intake: Polydipsia, thirst · Symptoms: Nocturia, frequency · Other: Weight loss, fatigue · Medications: Diuretics, lithium, etc. · Family history: Diabetes mellitus, diabetes insipidus Examination · Hydration status: Dehydration, volume status · Blood pressure: Hypertension, hypotension · Signs: Polyuria, weight loss, dehydration B. Baseline Investigations 1. Serum and Urine Osmolality Finding Interpretation Serum osmolality > 300 mOsm/kg Osmotic diuresis (glucose, mannitol, urea) Serum osmolality < 275 mOsm/kg Water diuresis (diabetes insipidus, primary polydipsia) Serum osmolality normal (280-295) Primary polydipsia (if urine osmolality low) Urine osmolality < 300 mOsm/kg Water diuresis (DI, polydipsia) Urine osmolality > 600 mOsm/kg Osmotic diuresis 2. Serum and Urine Sodium Finding Interpretation Hypernatraemia (Na > 145 mmol/L) Water deficit (DI) Hyponatraemia (Na < 135 mmol/L) Water excess (primary polydipsia) Normal sodium May be mixed disorder 3. Fasting Plasma Glucose · Purpose: Rule out diabetes mellitus · Interpretation: > 7.0 mmol/L suggests diabetes mellitus 4. Serum Potassium and Calcium · Hypercalcaemia: Causes nephrogenic DI · Hypokalaemia: Causes nephrogenic DI 5. Renal Function Tests · Urea, creatinine, eGFR: Assess renal function · Impaired concentration: In chronic kidney disease 6. Urinalysis · Glucose: Glucosuria suggests diabetes mellitus · Protein: Proteinuria suggests renal disease · Microscopy: Sediment abnormalities Specific Investigations A. Water Deprivation Test Indication: Differentiate types of diabetes insipidus Procedure 1. Baseline: Plasma osmolality, urine osmolality, body weight 2. Withhold fluids: For 4-8 hours 3. Monitor: Weight, urine output, urine osmolality hourly 4. Stop criteria: Weight loss > 3%, hypernatraemia, inability to tolerate Interpretation Condition Response to Water Deprivation DDAVP Response Normal Urine osmolality > 800 mOsm/kg Minimal change Primary polydipsia Urine osmolality > 500 mOsm/kg Minimal change Central DI No increase (< 300 mOsm/kg) Increase > 50% Nephrogenic DI No increase (< 300 mOsm/kg) No increase (< 300 mOsm/kg) B. DDAVP (Desmopressin) Test Indication: Differentiate central from nephrogenic DI Procedure 1. After water deprivation: Administer DDAVP (2 µg IM/intranasal) 2. Measure: Urine osmolality 2 hours later 3. Interpretation: Rise in urine osmolality > 50% = central DI C. Imaging Studies MRI Brain · Purpose: Identify hypothalamic-pituitary lesions · Findings: Pituitary stalk thickening, posterior pituitary bright spot Renal Ultrasound · Purpose: Identify structural abnormalities · Findings: Hydronephrosis, renal stones, medullary nephrocalcinosis Differential Diagnosis of Polyuria Condition Mechanism Urine Osmolality Serum Osmolality Response to Water Deprivation DDAVP Response Diabetes mellitus Osmotic diuresis High (glucose) High (hyperglycaemia) Not applicable Not applicable Central DI ADH deficiency Low High No increase Increase Nephrogenic DI ADH resistance Low High No increase No increase Primary polydipsia Water excess Low Normal/low Increase Minimal change Chronic kidney disease Impaired concentration Low (impaired) Normal Variable Minimal change Management Implications Diagnosis Management Diabetes mellitus Glycaemic control, treat underlying cause Central DI Desmopressin (DDAVP) Nephrogenic DI Thiazide diuretics (paradoxical), dietary modification, treat underlying cause Primary polydipsia Reduce water intake, treat psychiatric cause Chronic kidney disease Treat underlying cause, manage renal function 7. DIFFERENTIATION OF POLYURIA ASSOCIATED WITH DIFFERENT DISEASES A. Cerebral Diabetes Insipidus (Central DI) Pathophysiology · Deficiency: ADH production · Causes: Trauma, tumours, infection, genetic · Features: Polyuria, polydipsia, hypernatraemia Water Deprivation Test · Response: Urine osmolality < 300 mOsm/kg · DDAVP response: Increase in urine osmolality (> 50%) B. Nephrogenic Diabetes Insipidus (NDI) Pathophysiology · Defect: Impaired renal response to ADH · Causes: Genetic, drug-induced (lithium), hypercalcaemia, hypokalaemia Water Deprivation Test · Response: Urine osmolality < 300 mOsm/kg · DDAVP response: No increase in urine osmolality C. Renal Diseases (Increased Plasma Urea and Creatinine) Pathophysiology · Impaired concentration: Chronic kidney disease · Osmotic diuresis: Urea retention Features · Polyuria: Impaired concentration · Elevated urea and creatinine: Renal impairment · Proteinuria: Often present · Osmolality: Impaired concentration Water Deprivation Test · Response: Impaired (urine osmolality < 600 mOsm/kg) · DDAVP response: Minimal increase D. Hysterical Overdrinking (Primary Polydipsia) Pathophysiology · Excessive water intake: Suppresses ADH · Features: Polyuria, polydipsia, diluted urine Water Deprivation Test · Response: Urine osmolality > 500 mOsm/kg · DDAVP response: Minimal increase Comparison Table Feature Cerebral DI Nephrogenic DI Renal Disease Primary Polydipsia ADH levels Low Normal/high Variable Low Urine osmolality < 300 < 300 < 600 < 300 Plasma osmolality High High Normal Low-normal Serum Na■ High High Normal Low-normal Urea/creatinine Normal Normal Elevated Normal Water deprivation No increase No increase Some increase Increase DDAVP response Increase No increase Minimal Minimal 8. DISTINGUISHING LABORATORY FINDINGS IN RENAL DISEASES A. Acute Tubular Necrosis (ATN) Pathophysiology · Ischaemic injury: Reduced renal blood flow · Toxic injury: Nephrotoxins · Features: Acute kidney injury, oliguria Laboratory Findings Test Finding Mechanism Creatinine Elevated Reduced GFR Urea Elevated Reduced GFR FENa 2% Tubular damage FEUrea 35% Tubular damage Urine osmolality Low (< 350 mOsm/kg) Tubular dysfunction Urine Na■ 20 mmol/L Tubular dysfunction Sediment Muddy brown casts, tubular cells Tubular injury B. Renal Tubular Acidosis (RTA) Type 1 (Distal RTA) · Defect: Impaired distal H■ secretion · Features: Hyperchloraemic metabolic acidosis, hypokalaemia Type 2 (Proximal RTA) · Defect: Impaired proximal HCO■■ reabsorption · Features: Hyperchloraemic metabolic acidosis, hypokalaemia Type 4 (Hyperkalaemic RTA) · Defect: Aldosterone deficiency or resistance · Features: Hyperkalaemia, hyperchloraemic metabolic acidosis Laboratory Findings Test Type 1 RTA Type 2 RTA Type 4 RTA Urine pH 5.5 5.5 5.5 FEHCO■ < 5% 5% < 5% K■ Low Low High Urine NH■■ Low Normal/high Low Urine anion gap Positive Negative Positive C. Chronic Renal Failure (CRF) Pathophysiology · Progressive loss: Nephron loss → GFR reduction · Uraemia: Accumulation of waste products · Complications: Anaemia, bone disease, electrolyte disturbances Laboratory Findings Test Finding Mechanism Creatinine Elevated Reduced GFR Urea Elevated Reduced GFR eGFR Reduced Reduced GFR Potassium Elevated (with GFR < 10 mL/min) Reduced excretion Phosphate Eleva
Liver
Standard Answer:
1. PREHEPATIC JAUNDICE Definition Prehepatic jaundice (also called haemolytic jaundice) is a type of jaundice caused by excessive breakdown of red blood cells, leading to increased production of bilirubin. The problem occurs before the liver processes bilirubin. Pathophysiology A. Normal Bilirubin Metabolism 1. Haemoglobin breakdown: RBCs → Haem → Biliverdin → Bilirubin 2. Bilirubin: Unconjugated (indirect) bilirubin 3. Transport: Bound to albumin (insoluble in water) 4. Liver uptake: Hepatocytes take up bilirubin 5. Conjugation: UDP-glucuronyltransferase → Conjugated bilirubin 6. Excretion: Into bile → Intestine B. Mechanism of Prehepatic Jaundice 1. Increased RBC destruction: Haemolysis 2. Increased bilirubin production: Unconjugated bilirubin 3. Overload of liver: Exceeds conjugation capacity 4. Unconjugated bilirubin: Accumulates in blood 5. Jaundice: Unconjugated hyperbilirubinaemia Causes of Prehepatic Jaundice A. Intrinsic RBC Defects Cause Mechanism Examples Membrane defects Increased fragility Hereditary spherocytosis, elliptocytosis Enzyme defects Impaired metabolism G6PD deficiency, pyruvate kinase deficiency Haemoglobinopathies Abnormal haemoglobin Sickle cell disease, thalassaemia Paroxysmal nocturnal haemoglobinuria Membrane defect Acquired B. Extrinsic RBC Defects Cause Mechanism Examples Immune haemolysis Antibody-mediated Autoimmune haemolytic anaemia, transfusion reactions Microangiopathic haemolysis Mechanical damage TTP, HUS, DIC Infections Direct RBC damage Malaria, babesiosis, sepsis Drugs Oxidative damage Sulfonamides, dapsone, nitrofurantoin Toxins Direct damage Snake venom, lead Clinical Features Feature Description Jaundice Yellow discolouration of skin and sclera Anaemia Fatigue, pallor, dyspnoea Splenomegaly Enlarged spleen (extramedullary haematopoiesis) Gallstones Pigment stones (from increased bilirubin) Dark urine Increased urobilinogen (no bilirubin) Pale stools Normal or pale (no bilirubin) Laboratory Findings Test Prehepatic Jaundice Mechanism Total bilirubin Elevated Increased production Unconjugated bilirubin Elevated Overload of conjugation Conjugated bilirubin Normal Liver function intact Urine bilirubin Negative Unconjugated bilirubin not excreted Urine urobilinogen Increased Increased bilirubin in gut Haemoglobin Low Anaemia Reticulocyte count Elevated Compensatory erythropoiesis LDH Elevated Haemolysis Haptoglobin Low Haemoglobin binding ALT/AST Normal No liver damage Differential Diagnosis Feature Prehepatic Hepatic Posthepatic Bilirubin type Unconjugated Mixed Conjugated Urine bilirubin Negative Positive Positive Urine urobilinogen Increased Increased/decreased Decreased ALT/AST Normal Elevated Variable ALP Normal Normal/elevated Elevated Anaemia Present Variable Absent Stools Normal Variable Pale Management Aspect Management Treat underlying cause Identify and treat haemolysis cause Supportive care Iron and folic acid supplementation Blood transfusion For severe anaemia Splenectomy For hereditary spherocytosis (if indicated) Immunosuppression For autoimmune haemolytic anaemia Prevent complications Monitor for gallstones, renal failure Complications Complication Mechanism Management Gallstones Pigment stones Cholecystectomy Renal failure Haemoglobinuria Hydration, renal support Anaemia Chronic haemolysis Iron and folic acid Transfusion reactions Immunological Careful cross-matching 2. INHERITED DISORDERS OF BILIRUBIN METABOLISM IN HUMANS Introduction Inherited disorders of bilirubin metabolism result from genetic defects in the enzymes involved in bilirubin uptake, conjugation, and excretion. Classification Disorder Defect Type Inheritance Gilbert's syndrome Reduced conjugation Unconjugated Autosomal dominant Crigler-Najjar syndrome type 1 No conjugation Unconjugated Autosomal recessive Crigler-Najjar syndrome type 2 Reduced conjugation Unconjugated Autosomal recessive Dubin-Johnson syndrome Impaired excretion Conjugated Autosomal recessive Rotor syndrome Impaired excretion Conjugated Autosomal recessive A. Gilbert's Syndrome Definition: Benign condition characterized by mild unconjugated hyperbilirubinaemia due to reduced UDP-glucuronyltransferase activity. Pathophysiology · Defect: Mutation in UGT1A1 promoter (TA repeat) · Effect: Reduced gene expression (70% reduction) · Conjugation: Reduced bilirubin conjugation · Result: Mild unconjugated hyperbilirubinaemia Clinical Features · Asymptomatic: Usually incidental finding · Jaundice: Mild, intermittent · Triggers: Fasting, illness, exercise, stress · Normal: No liver disease, no anaemia Diagnosis Test Finding Total bilirubin 17-50 µmol/L (mildly elevated) Unconjugated bilirubin 80% of total Conjugated bilirubin Normal ALT/AST Normal Haemoglobin Normal Management · Reassurance: Benign condition · No treatment: Required · Avoid: Precipitating factors Prognosis: Excellent, no complications B. Crigler-Najjar Syndrome Type 1 (Severe) Pathophysiology · Defect: Complete absence of UDP-glucuronyltransferase activity · Enzyme: UGT1A1 completely deficient · Bilirubin: Markedly elevated (300-800 µmol/L) · Result: Severe unconjugated hyperbilirubinaemia Clinical Features · Severe jaundice: Neonatal period · Kernicterus: Bilirubin encephalopathy · Neurological damage: Severe · Death: Early childhood (without treatment) Diagnosis Test Finding Total bilirubin 300-800 µmol/L Unconjugated bilirubin 90% of total Liver function Normal Haemoglobin Normal Management · Phototherapy: Lifelong · Liver transplantation: Curative · Drugs: Phenobarbital (ineffective) · Monitor: Bilirubin levels Prognosis: Without liver transplant, early death from kernicterus Type 2 (Mild) Pathophysiology · Defect: Partial deficiency of UDP-glucuronyltransferase · Enzyme: UGT1A1 partially deficient (10-30% activity) · Bilirubin: 100-300 µmol/L · Result: Moderate unconjugated hyperbilirubinaemia Clinical Features · Jaundice: Variable · Kernicterus: Rare (but possible) · Response: To phenobarbital Diagnosis Test Finding Total bilirubin 100-300 µmol/L Unconjugated bilirubin 80% of total Liver function Normal Response to phenobarbital Positive Management · Phototherapy: As needed · Phenobarbital: Reduces bilirubin · Liver transplantation: Rarely needed · Monitor: Neurological status Prognosis: Variable, but generally better than type 1 C. Dubin-Johnson Syndrome Definition: Benign condition characterized by conjugated hyperbilirubinaemia due to impaired biliary excretion. Pathophysiology · Defect: Mutation in ABCC2 gene (MRP2) · Effect: Impaired biliary excretion of bilirubin · Bilirubin: Conjugated (direct) hyperbilirubinaemia · Liver: Dark pigmentation (black liver) Clinical Features · Jaundice: Mild, intermittent · Asymptomatic: Usually incidental · Drugs: May increase bilirubin · Pregnancy: May worsen Diagnosis Test Finding Total bilirubin 20-100 µmol/L Conjugated bilirubin 50% of total Urine bilirubin Positive Liver biopsy Black pigment Coproporphyrin isomers Abnormal Management · Reassurance: Benign · No treatment: Required · Avoid: Hepatotoxic drugs · Monitor: Liver function Prognosis: Excellent, no liver damage D. Rotor Syndrome Definition: Benign condition similar to Dubin-Johnson but without black liver pigment. Pathophysiology · Defect: Impaired hepatic storage and excretion · Mechanism: Unknown (possible transporter defect) · Bilirubin: Conjugated (direct) hyperbilirubinaemia · Liver: No pigment deposition Clinical Features · Jaundice: Mild · Asymptomatic: Incidental finding · Drugs: May increase bilirubin Diagnosis Test Finding Total bilirubin 20-100 µmol/L Conjugated bilirubin 50% of total Urine bilirubin Positive Liver biopsy Normal (no pigment) Coproporphyrin isomers Normal Management · Reassurance: Benign · No treatment: Required · Monitor: Liver function Prognosis: Excellent Comparison of Inherited Bilirubin Disorders Disorder Bilirubin Type Bilirubin Level Urine Bilirubin Liver Function Treatment Gilbert's Unconjugated 17-50 µmol/L Negative Normal None Crigler-Najjar I Unconjugated 300-800 µmol/L Negative Normal Phototherapy, transplant Crigler-Najjar II Unconjugated 100-300 µmol/L Negative Normal Phenobarbital Dubin-Johnson Conjugated 20-100 µmol/L Positive Normal None Rotor Conjugated 20-100 µmol/L Positive Normal None 3. UNCONJUGATED HYPERBILIRUBINAEMIA Definition Unconjugated hyperbilirubinaemia is an elevated level of unconjugated (indirect) bilirubin in the blood. It results from: 1. Increased production (haemolysis) 2. Decreased uptake (liver disease) 3. Decreased conjugation (genetic defects) Causes of Unconjugated Hyperbilirubinaemia A. Increased Production (Prehepatic) Haemolytic Anaemias · Intrinsic: Hereditary spherocytosis, G6PD deficiency, sickle cell disease · Extrinsic: Autoimmune, transfusion reactions, drugs · Other: Sepsis, malaria Ineffective Erythropoiesis · Causes: Megaloblastic anaemia, thalassaemia, sideroblastic anaemia · Mechanism: Premature RBC destruction in marrow · Result: Increased bilirubin production Blood Transfusion · Cause: Increased RBC breakdown · Mechanism: Transfusion of damaged cells B. Decreased Uptake Liver Disease · Causes: Hepatitis, cirrhosis, Wilson's disease · Mechanism: Reduced hepatic uptake · Result: Unconjugated bilirubin in blood C. Decreased Conjugation Gilbert's Syndrome · Cause: Reduced UDP-glucuronyltransferase activity · Features: Mild, benign Crigler-Najjar Syndrome · Type 1: Complete deficiency (severe) · Type 2: Partial deficiency (moderate) Neonatal Jaundice · Cause: Immature conjugation system · Features: Physiological jaundice Clinical Features Feature Description Jaundice Yellow discolouration of skin and sclera Anaemia In haemolytic causes Splenomegaly In chronic haemolysis Gallstones Pigment stones Kernicterus Bilirubin encephalopathy (severe) Laboratory Findings Test Finding Mechanism Total bilirubin Elevated Increased production or decreased conjugation Unconjugated bilirubin Elevated (> 80% of total) Defect in conjugation or uptake Conjugated bilirubin Normal Hepatic excretion intact Urine bilirubin Negative Unconjugated bilirubin not excreted Urine urobilinogen Increased (haemolysis) or normal Increased production ALT/AST Normal (except liver disease) No liver damage Diagnostic Approach Step 1: Confirm Unconjugated Hyperbilirubinaemia · Total and direct bilirubin: Direct < 20% of total · Indirect bilirubin: > 80% of total Step 2: Assess for Haemolysis · CBC: Anaemia, reticulocytosis · LDH: Elevated · Haptoglobin: Low · Peripheral smear: Schistocytes, spherocytes Step 3: Assess Liver Function · ALT/AST: Normal (unless liver disease) · ALP: Normal (no cholestasis) · Albumin: Normal Step 4: Assess for Inherited Disorders · Gilbert's syndrome: Mild (17-50 µmol/L), no haemolysis · Crigler-Najjar: Severe (300-800 µmol/L), no haemolysis · Family history: May be suggestive Step 5: Assess for Neonatal Causes · Physiological jaundice: Day 2-3, resolves by day 10 · Breast milk jaundice: Day 4-7, persists Treatment Condition Treatment Haemolytic anaemia Treat underlying cause (splenectomy, immunosuppression, etc.) Gilbert's syndrome Reassurance, avoid precipitating factors Crigler-Najjar type 1 Phototherapy, liver transplantation Crigler-Najjar type 2 Phenobarbital, phototherapy as needed Neonatal jaundice Phototherapy, exchange transfusion if severe Complications Complication Mechanism Management Kernicterus Bilirubin deposition in basal ganglia Phototherapy, exchange transfusion Gallstones Pigment stones Cholecystectomy Anaemia Chronic haemolysis Iron and folic acid Renal failure Haemoglobinuria Hydration, renal support 4. BILIRUBIN METABOLISM Introduction Bilirubin is a breakdown product of haemoglobin from red blood cells. Its metabolism involves: 1. Production 2. Transport 3. Uptake 4. Conjugation 5. Excretion Step 1: Production of Bilirubin Source · RBCs: 80% of bilirubin from senescent RBCs · Haemoproteins: Cytochrome P450, myoglobin, catalase (20%) Process 1. Macrophages: Spleen, liver, bone marrow phagocytose RBCs 2. Haemoglobin: Globin (recycled) + Haem 3. Haem oxygenase: Haem → Biliverdin + Fe²■ + CO 4. Biliverdin reductase: Biliverdin → Bilirubin Characteristics · Unconjugated: Water-insoluble (lipophilic) · Bound to albumin: Transported in plasma · Colour: Yellow Step 2: Transport Plasma · Albumin: Binds unconjugated bilirubin (high affinity) · Free bilirubin: Small fraction (toxic) · Toxicity: Free bilirubin crosses blood-brain barrier · Normal: Bilirubin completely bound to albumin Step 3: Hepatic Uptake Mechanism 1. Receptor-mediated: Hepatocyte membrane receptors 2. Transporters: OATP (organic anion transporting polypeptide) 3. Intracellular binding: Ligandin (glutathione-S-transferase) 4. Storage: In cytosol Regulation · Induction: Increased by phenobarbital · Inhibition: Decreased by liver disease Step 4: Conjugation Site: Hepatocyte endoplasmic reticulum (smooth ER) Enzyme: UDP-glucuronyltransferase (UGT1A1) Process 1. Unconjugated bilirubin: Bilirubin + glucuronic acid 2. Bilirubin monoglucuronide: One glucuronic acid molecule 3. Bilirubin diglucuronide: Two glucuronic acid molecules 4. Conjugated bilirubin: Water-soluble, excreted in bile Characteristics · Water-soluble: Excreted in bile · Toxicity: Non-toxic (unlike unconjugated) · Colour: Yellow Step 5: Excretion Biliary Excretion 1. Bile canaliculus: Conjugated bilirubin secreted into bile 2. Transporter: MRP2 (multidrug resistance protein 2) 3. Bile: Contains bilirubin diglucuronide 4. Intestine: Bilirubin reaches intestine Intestinal Metabolism 1. Bacteria: Hydrolyse glucuronides 2. Reduction: Bilirubin → Urobilinogen (colourless) 3. Oxidation: Urobilinogen → Stercobilin (brown) 4. Fate: · Feces: Stercobilin (stool colour) · Urine: Urobilinogen (reabsorbed → kidney → urine) Clinical Significance Disorder Defect Laboratory Finding Prehepatic jaundice Increased production Unconjugated bilirubin elevated, urine bilirubin negative Hepatic jaundice Impaired uptake/conjugation/excretion Mixed hyperbilirubinaemia, urine bilirubin positive Posthepatic jaundice Impaired excretion Conjugated bilirubin elevated, urine bilirubin positive, pale stools Gilbert's syndrome Reduced conjugation Unconjugated bilirubin elevated (mild) Crigler-Najjar syndrome Conjugation defect Unconjugated bilirubin elevated (severe) Dubin-Johnson syndrome Excretion defect Conjugated bilirubin elevated 5. DETAILED ESSAY ON BILIRUBIN METABOLISM AND ITS DISORDERS (See previous sections for detailed content) 6. LIVER FUNCTION TESTS AND THEIR USE IN ASSESSING LIVER DISEASE Introduction Liver function tests (LFTs) are a group of biochemical tests used to assess the functional status of the liver and detect liver disease. Categories of LFTs Category Tests What They Assess Hepatocellular injury ALT, AST Hepatocyte damage Cholestasis ALP, GGT, bilirubin Biliary obstruction Synthetic function Albumin, PT/INR Hepatic synthesis Bilirubin metabolism Total, direct, indirect bilirubin Bilirubin handling Immunological Immunoglobulins, autoantibodies Liver disease aetiology Viral markers Hepatitis serology Viral hepatitis Individual Tests A. Alanine Aminotransferase (ALT) Source: Hepatocytes (predominantly) Normal: 5-40 U/L Elevation: Hepatocellular damage Specificity: Highly specific for liver (especially ALT) Causes of Elevation: · Viral hepatitis · Alcoholic hepatitis · Drug-induced liver injury · Non-alcoholic fatty liver disease · Cirrhosis B. Aspartate Aminotransferase (AST) Source: Hepatocytes, cardiac muscle, skeletal muscle, brain, kidney Normal: 5-40 U/L Elevation: Hepatocellular damage, muscle damage Specificity: Less specific than ALT Causes of Elevation: · Same as ALT · Muscle injury (myocardial infarction, rhabdomyolysis) AST/ALT Ratio: · < 1: Viral hepatitis, NAFLD · > 2: Alcoholic liver disease · > 3: Alcoholic hepatitis C. Alkaline Phosphatase (ALP) Source: Liver (biliary canaliculi), bone, intestine, placenta Normal: 50-250 U/L Elevation: Cholestasis, bone disease Specificity: Liver (with GGT), bone (with bone-specific ALP) Causes of Elevation: · Biliary obstruction · Cholestasis · Liver disease with cholestasis · Bone disease (Paget's, osteomalacia, fractures) · Pregnancy (placental) Isoenzymes: · Liver: Elevated in cholestasis · Bone: Elevated in bone disease · Placental: Elevated in pregnancy D. Gamma-Glutamyl Transferase (GGT) Source: Hepatocytes, biliary epithelium, kidney, pancreas Normal: 5-50 U/L Elevation: Cholestasis, enzyme induction Specificity: Liver (with ALP) Causes of Elevation: · Cholestasis (biliary obstruction) · Alcohol abuse (induction) · Drug-induced liver injury · Fatty liver disease ALP/GGT Relationship: · Both elevated: Hepatobiliary disease · ALP elevated, GGT normal: Bone disease · GGT elevated, ALP normal: Alcohol-induced, enzyme induction E. Total Bilirubin Source: Haemoglobin breakdown Normal: 3-17 µmol/L Elevation: Jaundice Causes: · Haemolysis (unconjugated) · Liver disease (mixed) · Biliary obstruction (conjugated) · Inherited disorders (Gilbert's, Crigler-Najjar, etc.) F. Direct (Conjugated) Bilirubin Normal: < 5 µmol/L Elevation: Biliary obstruction, liver disease Interpretation: · Indirect bilirubin = Total - Direct · Direct > 50% of total: Conjugated hyperbilirubinaemia · Direct < 20% of total: Unconjugated hyperbilirubinaemia G. Albumin Source: Hepatocytes Normal: 35-50 g/L Decreased: Reduced synthesis (liver disease), increased loss (nephrotic syndrome) Causes of Low Albumin: · Chronic liver disease (cirrhosis) · Nephrotic syndrome · Malnutrition · Protein-losing enteropathy H. Prothrombin Time (PT) / INR Source: Vitamin K-dependent factors (II, VII, IX, X) Normal: 12-15 seconds, INR 0.8-1.2 Prolonged: Liver disease (reduced synthesis), vitamin K deficiency Interpretation: · Corrected with vitamin K: Vitamin K deficiency · Not corrected with vitamin K: Liver disease Use of LFTs in Assessing Liver Disease A. Detecting Liver Disease Patterns of Liver Disease: Pattern ALT/AST ALP GGT Bilirubin Albumin PT Hepatocellular ↑↑ Normal Normal Normal/↑ Normal/↓ Normal Cholestatic Normal/↑ ↑↑ ↑↑ ↑↑ Normal Normal Cirrhosis ↑ Normal/↑ Normal/↑ ↑ ↓ ↑ Alcoholic ↑↑ (AST > ALT) ↑ ↑↑ ↑ ↓ ↑ B. Monitoring Disease Progression · Serial LFTs: Track changes over time · ALT/AST: Decrease indicates improvement · ALP/GGT: Decrease indicates resolution of cholestasis · Albumin/PT: Worsening indicates progression to cirrhosis C. Predicting Prognosis · Child-Pugh Score: Uses bilirubin, albumin, PT, ascites, encephalopathy · MELD Score: Uses bilirubin, INR, creatinine 7. EXTENSIVE ESSAY ON LIVER FUNCTION TESTS (See previous section for detailed content) 8. PLASMA ALBUMIN Definition Albumin is the most abundant plasma protein, synthesized exclusively by hepatocytes. It serves multiple functions and is a key marker of hepatic synthetic function. Structure and Properties Property Description Molecular weight 66.5 kDa Concentration 35-50 g/L Half-life 15-20 days Synthesis Hepatocytes Functions Osmotic pressure, transport, buffering Functions of Albumin A. Oncotic Pressure · Major contributor: 70-80% of plasma oncotic pressure · Mechanism: Colloid osmotic pressure · Consequence: Maintains intravascular volume Clinical Significance: · Low albumin: Reduced oncotic pressure → oedema · Ascites: In liver disease, nephrotic syndrome B. Transport Function Substance Binding Bilirubin Unconjugated bilirubin Free fatty acids Transport Hormones Steroid hormones, thyroid hormones Drugs Many drugs (e.g., warfarin, phenytoin) Metals Calcium, copper, zinc Toxins Various toxins C. Buffering · pH regulation: Albumin is an important buffer · Effect: Helps maintain blood pH D. Antioxidant · Free radical scavenging: Binds free radicals · Effect: Protects against oxidative stress Clinical Significance of Albumin A. Hypoalbuminaemia Causes: Category Examples Decreased synthesis Liver disease (cirrhosis, hepatitis), malnutrition Increased loss Nephrotic syndrome, protein-losing enteropathy, burns Increased catabolism Hyperthyroidism, sepsis, trauma Dilution Overhydration, pregnancy Consequences: · Oedema: Peripheral oedema, pulmonary oedema · Ascites: Fluid in peritoneal cavity · Reduced drug binding: Increased free drug levels · Impaired healing: Wound healing · Hypocalcaemia: Reduced calcium binding Treatment: · Treat underlying cause: Correct liver disease, kidney disease, etc. · Albumin infusion: For severe hypoalbuminaemia · Nutritional support: High protein intake B. Hyperalbuminaemia Causes: · Dehydration: Haemoconcentration · Burns: Haemoconcentration · Nephrotic syndrome: Reduced volume (relative) Significance: · Rare: Usually due to dehydration · Treatment: Correct fluid status Albumin and Calcium Correction Need for Correction: · Albumin binds calcium · Low albumin → Low total calcium (but ionized calcium may be normal) Corrected Calcium Formula: · Corrected Ca (mmol/L) = Measured Ca + 0.02 × (40 - Albumin) · If albumin is 30 g/L: Corrected Ca = Measured Ca + 0.2 Albumin and Prognosis Condition Albumin Level Prognostic Significance Cirrhosis Low Poor prognosis Nephrotic syndrome Low Disease severity Malnutrition Low Increased mortality Sepsis Low Increased mortality 9. LIVER ENZYMES IN DIAGNOSIS Introduction Liver enzymes are used to detect hepatocellular injury and cholestasis. They are useful in: 1. Detecting liver disease 2. Monitoring disease progression 3. Assessing response to treatment 4. Screening for liver disease Hepatocellular Enzymes A. Alanine Aminotransferase (ALT) · Source: Hepatocytes (predominantly) · Normal: 5-40 U/L · Elevation: Hepatocellular damage · Specificity: Highly specific for liver Causes of Elevated ALT: · Acute viral hepatitis (very high) · Alcoholic hepatitis (moderate) · Drug-induced liver injury (variable) · Non-alcoholic fatty liver disease (mild-moderate) · Cirrhosis (mild) B. Aspartate Aminotransferase (AST) · Source: Hepatocytes, cardiac muscle, skeletal muscle, brain, kidney · Normal: 5-40 U/L · Elevation: Hepatocellular damage, muscle damage · Specificity: Less specific than ALT Causes of Elevated AST: · Same as ALT · Muscle injury (myocardial infarction, rhabdomyolysis) AST/ALT Ratio: Ratio Interpretation < 1 Viral hepatitis, NAFLD > 2 Alcoholic liver disease > 3 Alcoholic hepatitis Cholestatic Enzymes A. Alkaline Phosphatase (ALP) · Source: Liver (biliary canaliculi), bone, intestine, placenta · Normal: 50-250 U/L · Elevation: Cholestasis, bone disease Causes of Elevated ALP: · Biliary obstruction (gallstones, tumour) · Cholestasis (intrahepatic) · Liver disease with cholestasis · Bone disease (Paget's, osteomalacia, fractures) · Pregnancy (placental) ALP Isoenzymes: Isoenzyme Source Elevation Liver Biliary canaliculi Cholestasis Bone Osteoblasts Bone disease Placental Placenta Pregnancy Intestinal Intestine Rare B. Gamma-Glutamyl Transferase (GGT) · Source: Hepatocytes, biliary epithelium, kidney, pancreas · Normal: 5-50 U/L · Elevation: Cholestasis, enzyme induction Causes of Elevated GGT: · Cholestasis (biliary obstruction) · Alcohol abuse (induction) · Drug-induced liver injury · Fatty liver disease ALP/GGT Relationship: ALP GGT Interpretation ↑↑ ↑↑ Hepatobiliary disease ↑↑ Normal Bone disease Normal ↑↑ Alcohol-induced, enzyme induction Other Enzymes A. Lactate Dehydrogenase (LDH) · Source: Hepatocytes, cardiac muscle, skeletal muscle, RBCs · Normal: 100-200 U/L · Elevation: Hepatocellular damage, many other causes Uses: · Non-specific: Elevated in many conditions · Useful for: Assessing haemolysis · Limitation: Not specific for liver B. 5'-Nucleotidase · Source: Biliary epithelium · Normal: 2-15 U/L · Elevation: Cholestasis · Useful for: Confirming liver origin of ALP Clinical Application A. Patterns of Enzyme Elevation Pattern ALT/AST ALP GGT Interpretation Hepatocellular ↑↑ Normal Normal Hepatocellular injury Cholestatic Normal/↑ ↑↑ ↑↑ Biliary obstruction Alcoholic ↑↑ (AST > ALT) ↑ ↑↑ Alcoholic liver disease Mixed ↑↑ ↑↑ ↑↑ Combined injury B. Differential Diagnosis ALT/AST ALP GGT Likely Diagnosis High Normal Normal Acute viral hepatitis Moderate High High Biliary obstruction High High High Drug-induced liver injury AST > ALT High High Alcoholic liver disease Mild Mild Normal NAFLD 10. NEONATAL HYPERBILIRUBINAEMIA Definition Neonatal hyperbilirubinaemia is elevated bilirubin in newborns. It is common and can be physiological or pathological. Physiology of Neonatal Bilirubin Factors Contributing to Neonatal Hyperbilirubinaemia: 1. Increased RBC turnover: Shorter lifespan (70-90 days vs. 120 days in adults) 2. Immature conjugation: Reduced UDP-glucuronyltransferase activity 3. Enterohepatic circulation: Increased reabsorption 4. Reduced hepatic uptake: Immature liver Classification A. Physiological Jaundice Features: · Onset: 24-48 hours after birth · Peak: 3-5 days (full-term), 5-7 days (premature) · Duration: Resolves by day 10 (full-term), 14 days (premature) · Bilirubin: < 200 µmol/L · Direct bilirubin: < 15% of total Mechanism: · Increased RBC breakdown · Immature conjugation · Enterohepatic circulation B. Pathological Jaundice Indications: · Onset: < 24 hours · Rise: > 85 µmol/L/day · Prolonged: > 14 days · Direct bilirubin: > 20% of total · Symptoms: Lethargy, poor feeding, vomiting Causes of Pathological Jaundice A. Haemolytic Causes Cause Mechanism Rhesus incompatibility Maternal antibodies cross placenta ABO incompatibility Maternal IgG antibodies G6PD deficiency Oxidative haemolysis Hereditary spherocytosis Membrane defect Haemolytic disease of newborn Immune-mediated B. Non-Haemolytic Causes Cause Mechanism Breast milk jaundice Inhibitory factor (β-glucuronidase) Crigler-Najjar syndrome Conjugation defect Gilbert's syndrome Conjugation defect Biliary atresia Biliary obstruction Hepatitis Liver infection Hypothyroidism Reduced conjugation Sepsis Impaired liver function Clinical Features Feature Physiological Jaundice Pathological Jaundice Onset 24-48 hours < 24 hours Peak 3-5 days Variable Duration < 10 days (full-term), < 14 days (premature) Prolonged (> 14 days) Bilirubin < 200 µmol/L 200 µmol/L Clinical features Well baby Lethargy, poor feeding, vomiting Investigation Test Purpose Interpretation Total bilirubin Quantify bilirubin Elevated Direct bilirubin Identify cause 20% = obstructive CBC Assess for anaemia Low haemoglobin = haemolysis Blood group (mother and baby) Detect ABO/Rh incompatibility Maternal antibodies Direct Coombs test Detect antibodies Positive = immune haemolysis Reticulocyte count Assess RBC production Elevated = haemolysis Liver function Assess liver disease ALT/AST elevated G6PD test Detect G6PD deficiency Low activity Thyroid function Assess hypothyroidism Low T4, high TSH Urine and stool colour Assess for obstruction Pale stools, dark urine Management A. Phototherapy Indication: Bilirubin > 200 µmol/L (or age-specific nomogram) Mechanism: Blue light converts unconjugated bilirubin to photo-isomers (water-soluble, excreted in urine) Procedure: · Light: Blue-green (450-470 nm) · Exposure: 12-24 hours/day · Monitor: Bilirubin levels Complications: Dehydration, rash, hyperthermia B. Exchange Transfusion Indication: Severe hyperbilirubinaemia, bilirubin encephalopathy Indications: · Bilirubin: > 400 µmol/L (full-term) · Symptoms: Kernicterus · Failure: Phototherapy fails Procedure: · Double-volume exchange: Removes bilirubin and antibodies · Blood: Compatible with mother and baby Complications: Hypocalcaemia, hypoglycaemia, thrombocytopenia C. Treat Underlying Cause Cause Treatment Haemolytic disease Exchange transfusion, IVIG Biliary atresia Surgery (Kasai procedure) Sepsis Antibiotics Hypothyroidism Thyroxine Breast milk jaundice Continue breastfeeding Complications Kernicterus (Bilirubin Encephalopathy) Definition: Bilirubin deposition in basal ganglia, causing neurological damage Risk Factors: · Severe hyperbilirubinaemia: > 400 µmol/L · Prematurity: < 37 weeks · Hypoxia: Birth asphyxia · Acidosis: Metabolic acidosis Clinical Features: · Acute: Lethargy, poor feeding, high-pitched cry · Chronic: Athetoid cerebral palsy, hearing loss, intellectual disability Prevention: Early identification and treatment of hyperbilirubinaemia 11. NEONATAL JAUNDICE (30-MARK QUESTION) Definition Neonatal jaundice is the yellow discolouration of the skin and sclera in newborns due to elevated bilirubin. It is the most common condition requiring medical attention in neonates. Causes of Neonatal Jaundice A. Physiological Jaundice Feature Description Incidence 60-80% of full-term, 80% of preterm Onset 24-48 hours after birth Peak 3-5 days (full-term), 5-7 days (preterm) Resolution Day 10 (full-term), day 14 (preterm) Bilirubin Usually < 200 µmol/L Mechanism Immature conjugation, increased RBC turnover, enterohepatic circulation B. Pathological Jaundice Onset < 24 hours · Haemolytic disease of newborn (Rh/ABO incompatibility) · G6PD deficiency · Hereditary spherocytosis · Sepsis Rapid Rise (> 85 µmol/L/day) · Haemolysis (same as above) · Hepatic disease (hepatitis, galactosaemia) Prolonged Jaundice (> 14 days) · Breast milk jaundice · Conjugated hyperbilirubinaemia (biliary atresia, cholestasis) · Hypothyroidism · Genetic disorders (Gilbert's, Crigler-Najjar) Direct Hyperbilirubinaemia (> 20% of total) · Biliary atresia · Neonatal hepatitis · Choledochal cyst · Galactosaemia Pathophysiology A. Physiological Jaundice 1. Increased RBC breakdown: Fetal RBCs have shorter lifespan 2. Immature conjugation: UGT1A1 activity low 3. Enterohepatic circulation: Bacterial flora absent → increased reabsorption 4. Reduced hepatic uptake: Immature liver B. Pathological Jaundice Haemolytic Causes · Immune-mediated: Rh incompatibility, ABO incompatibility · Red cell membrane defects: Hereditary spherocytosis · Red cell enzyme defects: G6PD deficiency, pyruvate kinase deficiency · Mechanism: Increased RBC destruction → Unconjugated bilirubin Obstructive Causes · Biliary atresia: Progressive biliary obstruction · Choledochal cyst: Cystic dilatation of common bile duct · Mechanism: Conjugated bilirubin in blood, pale stools, dark urine Hepatic Causes · Neonatal hepatitis: Viral (CMV, hepatitis B, rubella) · Metabolic disorders: Galactosaemia, tyrosinaemia, α1-antitrypsin deficiency · Mechanism: Impaired uptake, conjugation, or excretion Investigation A. Initial Investigations Test Purpose Interpretation Total bilirubin Quantify bilirubin Elevated Direct bilirubin Differentiate cause 20% = obstructive CBC, blood group Detect haemolysis Anaemia, reticulocytosis Direct Coombs test Immune haemolysis Positive = immune G6PD screen Enzyme defect Low activity B. Further Investigations Test Purpose Interpretation LFT Assess liver damage ALT/AST elevated Hepatitis serology Detect viral hepatitis Positive antibodies Thyroid function Detect hypothyroidism Low T4, high TSH Urine for reducing substances Detect galactosaemia Positive Abdominal ultrasound Detect biliary atresia Gallbladder absent HIDA scan Confirm biliary obstruction No excretion into gut Liver biopsy Confirm diagnosis Bile duct proliferation Treatment A. Phototherapy Indication: Bilirubin > 200 µmol/L (or age-specific nomogram) Mechanism: Phototherapy converts unconjugated bilirubin to photo-isomers Protocol: · Type: Blue light (450-470 nm) · Duration: Continuous, 12-24 hours · Monitoring: Daily bilirubin · Complications: Dehydration, rash, hyperthermia Response: Bilirubin falls by 30-40% over 24 hours B. Exchange Transfusion Indication: Severe hyperbilirubinaemia, kernicterus Indications: · Bilirubin: > 400 µmol/L (full-term), > 300 µmol/L (preterm) · Symptoms: Kernicterus · Failure: Phototherapy fails Protocol: · Double-volume: 2 × blood volume · Blood: Cross-matched, O-negative · Monitor: Bilirubin, electrolytes, glucose Complications: Hypocalcaemia, hypoglycaemia, thrombocytopenia, infection C. Specific Treatment Cause Treatment Rh incompatibility Exchange transfusion, IVIG ABO incompatibility Exchange transfusion, IVIG Biliary atresia Kasai procedure (within 60 days) Galactosaemia Galactose-free diet G6PD deficiency Avoid precipitating drugs Hypothyroidism Thyroxine replacement Sepsis Antibiotics